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ABSTRACT
TREATMENT OF DUAL DIAGNOSIS POST TRAUMATIC STRESS DISORDER
AND SUBSTANCE USE DISORDERS: A META-ANALYSIS

Joshua Dolan
Marquette University

The dual diagnosis of post-traumatic stress disorder and substance use disorders
affects a large number of people. Various treatments have been used for addressing these
co-occurring disorders and have now been empirically tested. These treatments can be
divided into two categories: sequential and integrated. The goal of this study was to metaanalytically examine the effectiveness of these treatments and compare these two
categories of treatment. Secondary objectives included the exploration of potential
moderator variables and the symptom interplay between the two disorders after treatment.
The results of the study suggested that treatment for the dual diagnosis of posttraumatic stress disorder and substance use disorders is generally effective. There were
no major differences, however, between the two categories of treatment. There also was
no evidence of symptom interplay. There were no clear moderators. There was also
evidence that outcomes in this area of the research literature are being affected by the
“file drawer” problem, though likely not to a degree that would greatly weaken these
results.
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CHAPTER I
OVERVIEW
Post-Traumatic Stress Disorder (PTSD) and Substance Use Disorders (SUD) each
involve symptoms that can be quite debilitating (American Psychological Association,
2000). Individually, each of these disorders affects a large number of people, and a large
number of people are affected by the combination of the disorders occurring
simultaneously (American Psychological Association, 2000; National Center for PTSD,
2008; Substance Abuse and Mental Health Services Administration, 2006). When they do
occur together, the resulting syndrome can be very difficult for afflicted individuals to
cope with and for health care providers to treat.
To gain a full understanding of what the dual diagnosis looks like, one needs to
have a basic understanding of the presentation of each disorder alone. The Diagnostic and
Statistical Manual of Mental Disorders IV-Text Revision (DSM-IV-TR) (American
Psychiatric Association, 2000) describes PTSD as a set of symptoms that arise after an
individual experiences some kind of traumatic event such as injury or threat to self or
witnessing such an event toward another. This event must be responded to with fear,
helplessness, or horror. This event then leads to three symptom clusters: re-experiencing
the event, avoidance of event stimuli, and increased arousal. Re-experiencing the event
includes nightmares, flashbacks, dissociation, or intrusive thoughts. Avoiding stimuli
regarding the events refers to the individual’s attempts to avoid things that would remind
her or him of the event itself and which can lead to avoidance of particular people, places,
thoughts, or activities. The third symptom cluster, increased arousal, includes difficulty in
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falling asleep, hypervigilance, exaggerated startle reflex, or increased anger and
irritability.
PTSD is estimated to occur in about 8% of the United States population at some
point in their lives (American Psychiatric Association, 2000; National Center for PTSD,
2008). The National Center for PTSD (2008) further estimates that about 10% of women
and 5% of men can be diagnosed with PTSD in their lives. In terms of traumatic events,
this study estimated that about 60% of men report at least one traumatic event in their
lives while about 50% of women report the same.
For the purposes of this dissertation, SUD will be defined as either substance
abuse or dependence as described by the DSM-IV-TR (American Psychiatric
Association, 2000). The DSM-IV-TR defines substance abuse as a pattern of substance
use that leads to physically hazardous situations, legal or social problems, and a failure to
fulfill life responsibilities (i.e., work or family). Substance dependence is the more severe
disorder and includes tolerance effects, withdrawal, more substance use than intended,
failures to quit, a large amount of time spent in substance use activities, decrease in other
activities, and continued use despite the aforementioned problems. While the DSM-IVTR includes many different classes of substances within these categories, this review will
focus solely on alcohol and illegal drugs.
It is estimated that approximately 15% of the population meets the diagnostic
criteria for alcohol dependence sometime during their lifetimes (American Psychiatric
Association, 2000). Estimates for the lifetime prevalence for various illegal drugs are
1.5% for amphetamines, 5% for cannabis, 2% for cocaine, 0.6% for hallucinogens, and
0.7% for opioids (APA, 2000). It is estimated that twenty-two and a half million
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Americans (8.9% of the population twelve years of age and older) meet the criteria for a
SUD every year (Substance Abuse and Mental Health Services Administration, 2010).
There have been a wide range of prevalence estimates for the dual diagnosis of
SUD and PTSD. These estimates have ranged from 10.9% (Najavits, Runkel, et al., 2003)
to 41% (Brown, Read, & Kahler, 2003) for SUD treatment samples having comorbid
PTSD. More recent estimates have found 22.4% of individuals with cocaine dependence
and in treatment also had PTSD (Afful, Strickland, Cottler, & Bierut, 2010). Similar rates
have also been found across cultures with 25.3% of a German SUD treatment seeking
sample also having co-occurring PTSD (Driessen et al., 2008). One study examining
individuals in a PTSD treatment program found that 91.2% of the participants also had a
lifetime SUD diagnosis (Boudewyns, Woods, Hyer, & Albrecht, 1991). However, there is
reason to believe that participants of this last study had much more severe PTSD than
usual. Most of the other studies found comorbidity rates between 25% and 30%. These
rates seemed to hold across different age groups and countries. The highest prevalence
rate was found in a study of lower socioeconomic status (SES) inner-city women with
59% of the participants experiencing both SUD and PTSD (Fullilove et al., 1993),
suggesting that SES may play a role in the incidence of the comorbid syndrome. Given
the high rates of comorbid PTSD and SUD found across samples, some authors have
suggested that co-occurring disorders should be viewed as an expectation in the substance
abusing population (Minkoff & Cline, 2004). With these high rates, it is imperative that
effective treatments are found and utilized with this population.
Most studies of treatment outcomes for dual PTSD AND SUD individuals have
found that individuals with the dual diagnosis have worse outcomes than individuals with

Treatment of Dual Diagnosis 4
either disorder alone (Trafton, Minkel, & Humphreys, 2006). Mills, Teesson, Ross, and
Darke (2007) found mixed results where individuals with dual diagnoses improved more
on some measures but did worse on others. Brown, Stout, and Mueller (1996) found that
women with comorbid PTSD in an inpatient substance abuse treatment facility relapsed
faster after treatment then women in the same facility without PTSD. Surveys of
clinicians have found that they believe that the dual diagnosis is more difficult to work
with than either disorder alone (Najavits, 2002a). An early review of dual PTSD and
SUD suggested that the reasons that this dual diagnosis is difficult to treat are the
difficulty in assessment due to the amorphous nature of PTSD and that these individuals
have a tendency to isolate, have survivor guilt, suffer from depression, and have a great
deal of rage (Jelinek & Williams, 1984).
Furthermore, it appears that these individuals are not receiving the more
specialized treatment that they need. In a survey of women with dual PTSD and SUD,
Najavits, Sullivan, Schmitz, Weiss, and Lee (2004) found that the most utilized past
treatments in this population were individual psychotherapy, psychopharmacological
treatments, inpatient hospitalization, group psychotherapy, and SUD counseling. Only
about half of the participants were receiving treatment for both PTSD and SUD.
Chiavaroli (1992) examined the treatment files of individuals with a sexual abuse history
who were in a substance abuse treatment facility and found that their trauma was rarely
addressed.
Clients themselves report emotional pain, shame, and guilt as being the barriers to
getting treatment (Brown, Stout, & Gannon-Rowley, 1998). In a survey of clinicians
regarding difficulties surrounding treatment of this dual diagnosis, the clinicians reported
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clients’ self-destructiveness, case management needs, and dependency as the highest
ranked difficulties (Najavits, 2002a).
Statement of Problem
Considering the scope and nature of the PTSD and SUD dual diagnosis, it is
important that effective treatments be found. Up to this point, various treatment models
have been proposed and empirically tested for this dual diagnosis. However, a search of
the literature found no study that combined and compared these studies through metaanalysis. A number of isolated studies have been conducted on the interplay of the
symptoms in these two disorders, but there has not been a quantitative integration of
these studies.
Purpose
The purpose of this dissertation is to quantitatively examine the literature using a
meta-analytic approach to determine the effectiveness of treatment for the PTSD and
SUD dual diagnosis. Currently there is a movement toward integrated treatments for this
dual diagnosis, but there is as yet no examination regarding whether or not these
integrated treatments are any more effective than treatments aimed at either the PTSD or
SUD individually. Therefore, this study compared the effectiveness of integrated PTSD
and SUD treatments versus non-integrated treatments.
A secondary purpose was to explore the symptom interplay between the disorders
to determine how they affect each other throughout treatment and recovery. There are
numerous theories addressing how the different symptomologies affect one another, but
no empirical examination of this question has yet been conducted. Therefore, this study
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examined treatment follow-up data to compare PTSD and SUD symptoms over time to
determine if and how they interact.
Research Questions
1) What is the effectiveness of treatment for individuals with the dual diagnosis of
PTSD and SUD as measured by PTSD, SUD, and other psychological symptoms
between pre- and post-treatment?
2) Are there differences in the effectiveness of treatments between sequential and
integrated treatments for individuals with dual diagnosis PTSD and SUD?
3) Are there moderating influences on treatment outcomes for PTSD and SUD dual
diagnosis?
4) How do PTSD and SUD symptoms progress over time after treatment as
measured by symptom change scores at post-treatment and follow-up
measurements?
A meta-analytic technique was employed to answer these questions. The primary
procedure used was Hunter and Schmidt’s (2004) technique for meta-analysis and
correction. This procedure uses effect size data attained from individual studies and
statistically corrects for systematic errors and biases that may be occurring to attempt to
attain as accurate a view as possible of the true population effect size scores.
All meta-analyses are contingent upon the literature on which they are based. The
literature on dual diagnosis PTSD and SUD is still a relatively new one that is also
limited in size. As long as the literature base is sufficiently large, however, meta-analysis
can be quite useful for providing preliminary answers to the aforementioned research
questions.

Treatment of Dual Diagnosis 7
Definition of Terms
Particularly relevant terms used in this document are defined as follows.
Coding: Process of converting study information into useful meta-analytical data
(Stock, 1994).
Correction: Process of correcting for the various statistical and methodological
artifacts that have biased individual study effect sizes (Hunter & Schmidt, 2004).
Dual diagnosis: Diagnosis of two or more mental disorders within a single
individual (APA, 2000).
Integrated (or concurrent) treatments: Treatments for a dual diagnosis that treat
both diagnoses simultaneously (Back, Waldrop, Brady, & Hien, 2006).
Meta-analysis: Technique by which data from multiple independent sources can
be synthesized into a useful form (Hunter & Schmidt, 2004).
Moderator variable: Variable that may be causing variation in the results of an
analysis (Hunter & Schmidt, 2004).
Sequential treatments: Treatments for a dual diagnosis that focuses on a single
diagnosis first, before treating the second diagnosis (Back, Waldrop, Brady, & Hien,
2006).
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CHAPTER II
LITERATURE REVIEW
A discussion on the dual diagnosis of PTSD and SUD can be divided into two
main sections. The first of these sections examines diagnostic issues that include etiology,
maintenance, and presentation of the dual diagnosis. The second section will summarize
the treatment literature for dual SUD and PTSD.
Diagnostic Issues
Diagnostic issues regarding dual PTSD and SUD encompass the areas of etiology,
maintenance, and presentation. Knowledge of the development of dual diagnosis PTSD
and SUD can help inform the treatment of individuals with this comorbidity. For
example, if one of the disorders develops first and seems to underlie the other, then
treating that underlying disorder would become the primary therapeutic priority. Once
both disorders develop there are a variety of ideas on how they maintain each other.
Many of these theories describe a cyclical pattern in which symptoms of one disorder
lead to an increase in symptoms of the other. Information on maintenance can also help
inform and explain the behavioral patterns that are seen with this population.
Furthermore, once the comorbidity is established, it cannot be assumed that the client’s
symptomology is simply the two disorders’ symptomologies added together as they may
combine to form a syndrome whose total is greater than the sum of its parts and is
especially intractable and resistant to change. Thus, all three of these areas of etiology,
maintenance, and presentation can help inform treatment decisions.
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Etiology
There are a variety of theories on how the dual diagnosis develops. Some of these
theories state that one disorder causes the other, while others discuss some third variable,
such as genetics or some other factor, that serves as a vulnerability for both disorders.
Examples of factors that have been statistically significantly implicated in the
development of dual PTSD and SUD are low levels of education, high number of traumas
experienced, high perception of threat to life, and low social support (Ullman, Filipas,
Townsend, & Starzynski, 2006). Sociological factors such as culture, family environment
and poverty may also serve as vulnerabilities (Logan, Walker, Cole, & Leukefeld, 2002).
Research has identified the psychological factor of low self-regulatory ability as a
major vulnerability factor for the development of PTSD and SUD dual diagnosis (Hien,
Cohen, & Campbell, 2005; Khantzian, 1997). A similar construct, coping skills, has also
been suggested as a vulnerability (Simpson, Jakupcak, & Luterek, 2006; Ullman, Filipas,
Townsend, & Starzynski, 2005). These findings support the viewpoint that both disorders
are unhealthy ways of dealing with stressful life events.
Genetics and early family environment have also been suggested as potential third
variables. A study by Dierker and Merikangas (2001) found that a family history of SUD
increased the risk for PTSD by nearly four times. Xian et al. (2000) examined 3,000 twin
pairs who were male Vietnam War veterans and found that PTSD and SUD shared
additive genetic components as well as contributed distinct components accounting for
about 25% of the variance of the disorders.
The type of trauma that underlies the diagnosis of PTSD may also serve as a
vulnerability, as more severe forms of trauma significantly increase dual PTSD and SUD
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rates (Stewart, Mitchell, Wright, & Loba, 2004). These more severe forms of trauma
involve assaults by non-strangers, combat trauma, childhood trauma, and life threatening
illnesses (Brinson & Treanor, 1989; Dragan & Lis-Turlejska, 2007; Raghavan &
Kingston, 2006; Waldrop, Santa Ana, Saladin, McRae, & Brady, 2007). Stewart,
Mitchell, et al. (2004) found that individuals with PTSD were statistically significantly
more likely to use substances to cope following more severe traumas.
Another important question is if one disorder causes the other. Does SUD cause
PTSD or is it the other way around? Research has examined the temporal order of the
disorders, but the results are inconclusive with some studies finding that SUD tends to
precede PTSD (Kilpatrick, Ruggiero, et al., 2003; Cottler et al., 1992) while others
finding PTSD precedes SUD (Shipherd, Stafford, & Tanner, 2005; Mills, Teesson, Ross,
& Peters, 2006; Reed, Anthony, & Breslau, 2007; Chilcoat & Breslau, 1998). Some
neuropsychological studies suggest that stress and trauma can produce changes in the
brain that place an individual at greater risk for SUD (Goeders, 2003). Gender has also
been identified as a possible moderating variable that affects which disorder precedes the
other (Deykin & Buka, 1997; Jaycox, Ebener, Damesek, & Becker, 2004).
Many of these etiological studies that examined which disorder preceded the other
utilized large sample sizes, but the retrospective nature of these studies resulted in
findings susceptible to recall bias. Only a few utilized longitudinal designs (e.g. Shipherd
et al., 2005) that would not be susceptible to this type of bias. Furthermore, many utilized
measures of unknown (or unreported) psychometric quality, which weakened the
reliability of the results.
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Maintenance
Several proposals have been offered regarding how these two disorders maintain
each once they develop. Many of these proposals describe a cyclical pattern in which
symptoms of one disorder lead to an increase in the other disorder (Clark, Masson,
Delucchi, Hall, & Sees, 2001; Stewart & Conrod, 2003). The participants of a study of
combat experienced Vietnam veterans reported that the symptoms of both PTSD and
SUD increased simultaneously after the war (Bremmer, Southwick, Darnell, & Charney,
1996). A 20-year study of Vietnam veterans (Price, Risk, Haden, Lewis, & Spitznagel,
2004) found SUD appeared to exacerbate PTSD initially but as time went on the PTSD
appeared to lead to continuation of the SUD. Individuals with PTSD and SUD have also
reported that they believe that the symptoms of the two disorders are related to one
another (Brown, Stout, & Gannon-Rowley, 1998; Reynolds et al., 2005).
These findings suggest that once the dual disorder develops, each of the
components serves to maintain the other in some form of a positive feedback loop.
Potential processes by which the disorders may maintain each other include SUD
symptoms exacerbating and prolonging PTSD by preventing habituation to trauma, SUD
withdrawal symptoms being misinterpreted as PTSD symptoms, and SUD symptoms
retriggering PTSD symptoms through mechanisms such as sleep disturbances (Stewart,
Pihl, Conrod, & Dongier, 1998). This cycle can also occur through automatic processes
such as cue reactivity or other neurological processes (Cohen, Mannarino, Zhitova, &
Capone, 2003; Conrod & Stewart, 2003).
A theory used to describe how PTSD can lead to SUD symptoms is Khantzian’s
(1985; 1997) self-medication hypothesis. This hypothesis states that individuals use
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specific substances to self-medicate uncomfortable feelings or thoughts and alleviate
suffering. Stewart (1996) stated that binge drinking is triggered by increases in PTSD
symptoms because alcohol reduces tension, dampens physiological stress reactions,
reduces negative mood states and alexthymia, and reduces the intrusive symptoms of
PTSD. A factor analysis of PTSD found correlates with specific substances (Stewart,
Conrod, Pihl, & Dongier, 1999). Alcohol was found to be associated with arousal
symptoms, anxiolytics with arousal and numbing symptoms, and analgesics with arousal,
intrusions, and numbing symptoms. Jacobsen, Southwick, and Kosten (2001) stated that
depressants may cause arousal symptoms similar to those of PTSD.
A study of substance use relapse factors found that PTSD symptoms predicted
relapse in negative interpersonal, negative physiological, and social pressure situations
(Norman, Tate, Anderson, & Brown, 2007). Waldrop, Back, Verduin, and Brady (2007)
also found that individuals with dual diagnosis PTSD AND SUD were more likely to use
substances in negative situations such as the experience of negative emotions or physical
discomfort. One mixed methods study (Condon, 2004) interviewed ten individuals with
dual PTSD and SUD and found that the participants reported using substances to numb
feelings and forget negative memories.
The arousal symptom cluster of PTSD in particular seems to have the most effect
in maintaining SUD (Ouimette, Moos, & Brown, 2003; Stewart, Pihl, et al., 1998).
Alcohol abuse may increase arousal in individuals so that they are more likely to develop
and maintain PTSD (Stewart, 1996). Another study found that while all the PTSD
symptoms tended to decrease with time in participants who were assaulted in the
previous month, the arousal symptoms in those with alcohol use problems deceased less
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(Kaysen, Simpson, et al., 2006). In contrast, another study (Kaysen, Simpson, et al.,
2006) assessing women who had been assaulted in the previous month found that alcohol
use predicted intrusion and avoidance symptoms but not arousal symptoms after the
trauma.
Najavits, Runkel, et al. (2003) found that the arousal symptom set of PTSD was
most prominent in a sample of individuals with cocaine dependence and PTSD, which is
consistent with the stimulative properties of cocaine. Stewart, Mitchell, Wright, and Loba
(2004) found elevated hyper arousal and re-experiencing symptoms. Brown (2000) found
that the re-experiencing cluster of PTSD predicted future SUD and PTSD outcomes in 29
women who were in a non-PTSD focused multimodal treatment. Van Der kolk,
Greenburg, Boyd, and Krystal (1985) state that opiates have similar withdrawal
symptoms as the arousal symptoms of PTSD.
Brown, Read, and Kahler (2003) found that individuals in SUD treatment who
maintained their PTSD diagnosis from baseline to a 6-month follow-up had worse
substance use outcomes then those who remitted or those who did not have PTSD. The
individuals who experienced unremitted PTSD maintained their greater reliance on
negative coping styles while those who showed improvement had less negative coping
style reliance. In a re-examination of Brown, Read and Kahler’s (2003) data, Ouimette,
Coolhart, Funderburk, Wade, and Brown (2007) calculated odds ratios for relapse.
Participants with unremitted PTSD were 7.38 times more likely to use due to depression
then those participants without PTSD. Participants with PTSD were also statistically
significantly more likely to spend a lot of effort to get the substance, have more urges to
use, were more than three times more likely to think about using before the actual use and
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more than three times more likely to use to intoxication than those without PTSD. These
individuals with PTSD were also less likely to have confidence in their ability to avoid
relapse and use due to interpersonal pressures.
It appears that many factors interact with each other to maintain the dual
diagnosis. Each disorder is likely to maintain the other either directly and/or indirectly
through other factors. Gil-Rivas, Fiorentine, and Anglin (1996) found that while PTSD
was not associated directly with relapse, it was associated with a variety of factors such
as depression, self-esteem, and anxiety, all of which were correlated with relapse.
Presentation
Individuals with PTSD and SUD dual diagnosis present to treatment with a
variety of symptoms, some of which are a result of the individual disorders while others
result from the dual combination (Schafer & Najavits, 2007). These symptoms span the
biological, psychological and social domains of functioning.
Biological. The dual diagnosis of SUD and PTSD can have a large impact on
brain functioning. Some authors hypothesize that the dual diagnosis of PTSD and SUD
leads to impairments in executive functioning and memory, under-reactivity to visual
affective stimuli (due to PTSD numbing), and over-reactivity to trauma/drug related cues,
(Samuelson, et al., 2006; Sokhadze, et al., 2007). Other reviews (Brady & Sinha, 2005)
suggest that the HPA axis, extra-hypothalamic cortico-releasing factor (CRF), and the
noradrenergic system are all involved in this dual diagnosis. Increased levels of CRF may
enhance the addictive nature of some drugs and increase PTSD symptoms such as the
arousal set of symptoms. Brady, Waldrop et al. (2006) found that participants with the
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dual diagnosis experienced a neurological numbing but at the same time a subjective
heightening of stress reactions.
Individuals with dual PTSD and SUD also tend to have worse health outcomes
(Tate, Norman, McQuaid, & Brown, 2007; Mills, Teesson, Ross, & Peters, 2006; Brown,
Recupero, & Stout, 1995; Lester, 2007; Mills, Lynskey, Teesson, Ross, & Darke, 2005;
Kaysen, Pantalone et al., 2008; Peirce, Kindbom, Waesche, Yuscavage, & Brooner,
2008). Ouimette, Goodwin, and Brown (2006) found that those with SUD and PTSD selfreported more cardiovascular and neurological symptoms, as well as more chronic
physical symptoms than those with SUD only. A study (Waldrop, Back, Sensenig, &
Brady, 2008) examining the effects of PTSD and alcohol dependence on sleep found that
participants with PTSD and alcohol dependence had worse sleep quality (i.e. daytime
sleepiness or mid-sleep awakening) than participants without these disorders.
Brown, Stout, and Mueller (1999) calculated that individuals with dual PTSD and
SUD incurred $4,042 in inpatient addiction services while SUD-only individuals incurred
$780 during the same time period. Mills, Teesson, Ross, Darke, and Shanahan (2005)
also found that dual diagnosis trended toward more costs but not in a statistically
significant manner.
Psychological. Individuals with the dual diagnosis of PTSD and SUD are more
prone to other mental health disorders (Kovach, 1986; Lester, 2007; Peirce et al., 2008;
Brown, Stout, & Mueller, 1999; Read, Brown, & Kahler, 2004). Other studies have found
that those with SUD and PTSD have worse mental health functioning than those with
SUD only or those with no diagnosis (Mills, Lynskey, et al., 2005; Najavits, Harned, et
al., 2007; Ouimette, Goodwin, and Brown 2006; Trafton, Minkel, & Humphreys, 2006;
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Ullman, Townsend, Starzynski, Long, 2006) though Najavits, Weiss, and Shaw (1999)
did not find greater psychological symptoms among dual diagnosis women versus
women with PTSD only. Individuals with this dual diagnosis were more likely to use
multiple classes of drugs (Dragan & Lis-Turlejska, 2007; Mills, Lynskey, et al., 2005;
Peirce et al., 2008; Rotunda, O'Farrell, Murphy, & Babey, 2008) and have longer drug
use histories (Read, Brown, & Kahler, 2004; Trafton, Minkel, & Humphreys, 2006).
Other psychological processes also affected by this dual diagnosis. Individuals
with this dual diagnosis tend to have greater rates of suicidal ideation (Price et al., 2004;
Harvey, Rawson, & Obert, 1994) and attempts (Najavits, Weiss, & Shaw, 1999) than
individuals with either diagnosis alone. On measures of cognitive distortions, women
with dual PTSD and SUD scored higher than a PTSD only group (Najavits, Gotthardt,
Weiss, & Epstein, 2004). Najavits, Weiss, and Shaw (1999) found that women with dual
diagnosis PTSD and SUD were statistically significantly less resilient, while Ouimette,
Ahrens, Moos, and Finney (1998) found that individuals with dual diagnoses had lower
coping abilities than individuals with single diagnoses. Jaycox et al. (2004) found that
individuals with PTSD had statistically significantly more internalizing symptoms than
individuals with SUD or SUD with a history of trauma.
Social. Najavits, Harned et al. (2007) found that individuals with dual diagnosis
PTSD and SUD had statistically significantly more interpersonal problems than those
with SUD only. These interpersonal problems included difficulties with employment
(Peirce et al., 2008; Mills, Teesson, Ross, Darke, & Shanahan, 2005). Dual diagnosis
individuals have been found to have statistically significantly less education and income
than those with single SUD or PTSD (Riggs, Rukstalis, Volpicelli, Kalmanson, & Foa,
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2003; Ullman, Townsend, et al., 2006). Adolescents with co-occurring disorders had
more negative scores on measures of externalizing behaviors, arrests, and grade point
averages (Kilpatrick, Ruggiero, et al. 2003).
Riggs et al. (2003) found that individuals with this dual diagnosis were
statistically significantly less likely to be living with a partner then single diagnosed
individuals. These individuals have also been found to have high rates of intimacy and
sexuality issues (Levan, 2006). Women with dual PTSD and SUD have also reported
high rates of domestic violence (both physical and psychological) directed at them as
well as committed by them (Najavits, Sonn, Walsh, & Weiss, 2004; Parrott, Drobes,
Saladin, Coffey, & Dansky, 2003). In a study of aggression, the arousal symptoms of
PTSD were positively associated with aggression both directly as well as indirectly
through the effects of alcohol (Taft et al., 2007). Zoricic, Buljan, Thaller, and Karlovic
(2003) found that a group with PTSD and alcohol dependence displayed statistically
significantly more verbal and physical aggression than a group with just PTSD in a
sample of Croatian war veterans.
Summary
There are a variety of theories on how this dual diagnosis develops. A great deal
of research has been done examining various underlying factors such as genetics or a lack
of coping skills (Dierker & Merikangas, 2001; Simpson, Jakupcak, & Luterek, 2006). It
is also not yet clear if one disorder tends to precede the other though gender may be a
moderating variable on the temporal development of the disorders (Jaycox et al., 2004).
Studies that include multiple underlying factors should be used to determine which ones
best explain the development of the dual diagnosis.
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Once the dual disorder develops, the symptoms of one disorder appear to increase
the symptoms of the other. While a few hypotheses have been explored on how SUD
affects PTSD, more research has been done on how PTSD drives SUD. The most
prominent of these latter theories is the self-medication hypothesis (Khantzian, 1997).
Other studies have explored how specific symptom clusters are related to substance use,
though it is still not clear how these symptom clusters interact with each other or with the
substance abuse. It is also possible that the disorders interact through some other third
variable such as depression.
The dual diagnosis of PTSD and SUD represents a large cluster of potential
symptoms. Furthermore, it has been found to have many profound effects on other areas
of life functioning. Neurological studies have found changes in brain functioning
associated with this dual diagnosis (Brady & Sinha, 2005). These individuals are also
more prone to other physical and mental health issues (Tate et al., 2007; Brown, Stout, &
Mueller, 1999), and are more likely to have interpersonal issues (Riggs et al., 2003).
Research suggests that different individuals may develop the dual diagnosis
through different pathways and for different reasons. Once they have the dual disorder, it
perpetuates itself in a way that makes it difficult to treat. Unfortunately, the mechanisms
by which it develops and is maintained are not altogether clear. Furthermore, while a
great deal of research has been done on these mechanisms, the research is not to the point
that it can be clinically useful for more than broad generalizations.
Treatment
Many different treatment models have been proposed and tested to help clients
and therapists treat co-occurring PTSD and SUD. Some of these treatments were
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designed for treating PTSD or SUD individually and were subsequently used with
individuals with dual diagnoses. Other treatments were designed specifically to treat the
dual diagnosis. These later treatments integrate components that are believed to be
effective for both disorders. Various researchers have described the need for these
integrated treatments (Drake, Mercer-McFadden, Mueser, McHugo, & Bond, 1998;
Minkoff & Cline, 2004). Back, Waldrop, Brady, and Hien (2006) noted that treatments
for dual diagnoses can be divided into two categories: sequential and integrated. The
following sections will review both of these treatments in turn.
Sequential Treatments
Sequential treatments initially focus on only one of the diagnoses. Some of these
treatments focused on SUD as a primary diagnosis and used treatments such as 12-step or
relapse prevention models for SUD (Ouimette, Humphreys, et al., 2001). Other
treatments have focused on PTSD as a primary diagnosis and utilized treatments such as
exposure treatment. In one of the first articles offering suggestions for the treatment of
this dual diagnosis, Jelinek and Williams (1984) suggested that after a thorough
assessment is done, the client should be placed in the treatment that matches her or his
primary diagnosis. The subsequent sections will examine the results of these sequential
treatments.
SUD Treatment. Treatments for SUD have a long established history. Models for
recovery range from the Minnesota model (Anderson, McGovern, & DuPont, 1999) to
cognitive-behavior models such as Marlatt’s Relapse Prevention Model (Witkiewitz &
Marlatt, 2004). Many of these treatments have also been empirically tested with dual
diagnosis clients. Other treatments like motivational interviewing have been suggested as
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helpful but have not been empirically tested to demonstrate their usefulness with this dual
disorder (Feldstein & Ginsburg, 2006).
A study dealing with 12-step meeting participation and how that relates to
treatment outcomes for individuals with dual PTSD and SUD found that individuals with
this dual diagnosis were just as likely to attend Alcoholics Anonymous meetings as those
individuals with SUD only (Ouimette, Humphreys, et al., 2001). Attending these
meetings was associated with statistically significantly greater abstinence (r=.28), less
distress (r=.27), and better quality of social relationships (r=.38) at a one-year follow-up.
Ouimette, Ahrens, Moos, and Finney (1998) examined data from a variety of VA
hospitals that offered treatments based on both cognitive behavioral (CBT) and 12-step
models for SUD but no treatments aimed specifically at PTSD. Substance abuse
counseling, family counseling, and 12-step involvement were associated with lower
psychological symptoms among the individuals with dual PTSD and SUD at discharge. A
one-year follow-up with these individuals found treatment gains were maintained with
SUD outcomes but not for outcomes of psychological symptoms, employment, coping,
and use expectancy measures (Ouimette, Ahrens, Moos, & Finney, 1997). The SUD
outcomes were also maintained at a two-year follow-up (Ouimette, Finney, & Moos,
1999).
A study of CBT treatment for SUD found that in a group of individuals with dual
PTSD and SUD, nearly 80% of the participants showed improvement for at least one of
their diagnoses, with close to half showing improvement on both (Back, Brady, Sonne, &
Verduin, 2006). An examination of the process of improvement during this study showed
that alcohol symptoms decreased before PTSD symptoms, though the PTSD symptoms
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were assessed less regularly, which weakens this particular result. Furthermore, reduction
in PTSD symptoms (mainly the arousal symptoms) was associated with lower drinking
rates, but not the other way around, which the authors interpreted as meaning that PTSD
symptoms mediate the SUD.
Behavioral couples therapy (BCT) has also been suggested as a possible therapy
for individuals with this dual diagnosis and their partners (Rotunda et al., 2008). Male
veterans with PTSD and SUD were demographically matched with 19 other veterans who
did not have PTSD. Both groups attended BCT treatment. The results showed gains for
all of the individuals involved in BCT on drinking (r=.63), relationship (r=.30), and
psychological distress outcomes (r=.33), but with no statistically significant differences
between the groups. Unfortunately, improvements in PTSD outcomes were not reported.
Najavits, Harned, et al. (2007) examined the outcomes among a group of
individuals with cocaine dependence only and a group with cocaine dependence and
PTSD. Participants were recruited from a variety of outpatient treatment modalities that
used manualized SUD treatment: individual cognitive therapy, individual supportiveexpressive therapy, psychodynamic treatment, individual 12-step drug counseling, and
group 12-step drug counseling. The PTSD group displayed statistically significant
improved scores in global psychological symptoms, but not in addiction or interpersonal
functioning. However, this may have been due to the PTSD group’s more severe global
psychological symptom scores at intake. Overall, the study suggested that dual diagnosis
clients begin treatment with greater symptomatology and do not show as much
improvement.
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A dissertation (Lester, 2007) based on data from a larger study examined the
effects of contingency management versus contingency management plus day treatment
on individuals that were homeless and had cocaine dependence. This study found that
while the group with co-occurring PTSD was not statistically significantly different in
number of weeks abstinent or in relapse rates, they did relapse sooner after treatment on
average than the non-PTSD group. Individuals with the dual diagnosis in the day
treatment program showed improvements on PTSD symptoms over those in the
contingency management group, however improvements in PTSD symptoms were not
associated with improvements in SUD outcomes.
Coffey, Schumacher, Brady, and Cotton (2007) studied how PTSD and SUD
symptoms remit over a month long abstinence during SUD treatment (which was not
described in the study). PTSD symptomology was found to decrease for the first two
weeks but then level off, with a trend toward increasing but not at a statistically
significantly level. Unfortunately, even after the leveling off, PTSD was still occurring at
clinically significant levels.
Most of these studies suggested that SUD treatment has a positive effect on this
dual diagnosis. Unfortunately, many of the studies did not provide treatment adherence
data. Furthermore, there was rarely any control over potential outside treatments. These
weaknesses make it difficult to pinpoint the cause of the outcomes with certainty.
Diagnosis was also an issue as some articles only used chart review as a basis for
diagnosis.
PTSD Treatment. There have been a variety of treatments that have been shown to
be effective with PTSD (Adshead, 2000). Most of these treatments are exposure based
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therapies as well as interventions that attempt to teach the client coping skills or to help
the client find meaning in life. Exposure based treatments are the premiere therapies for
PTSD and entail some kind of reprocessing of the trauma (Powers, Halpern, Ferenschak,
Gillihan, & Foa, 2010). Traditionally, these exposure based treatments for the dual
diagnosis of PTSD and SUD were typically discouraged, as they were believed to
potentially increase chances of relapse.
A study (Coffey, Stasiewicz, Hughes, & Brimo, 2006) examining whether
exposure therapy would lower subjective ratings of craving and negative affect used a
sample of 43 individuals with dual PTSD and alcohol dependence randomly assigned to
either a relaxation treatment or imaginal exposure treatment. The results showed a
statistically significant decrease in measurements of craving and negative affect for those
who were in the exposure group as opposed to the relaxation group, with very high
correlation values (r = .89 and .94 for craving and subjective discomfort) between the two
groups. The exposure group also had lower PTSD symptoms after the imaginal exposure
treatment (r=.62) than the relaxation group. While only 50% of the participants
completed the exposure treatment, there was no statistically significant difference
between the groups on attrition. A reanalysis of the treatment attrition group found that
negative affect, PTSD severity, alcohol craving, study condition (imaginal exposure vs.
relaxation), and cocaine dependence were not associated with greater treatment drop-out
rates, though higher negative affect trended toward statistical significance (Hughes,
2007).
Ouimette, Moos, and Finney (2003) provided further evidence for the efficacy of
PTSD treatment on long-term SUD outcomes. The authors examined 118 individuals
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who had PTSD and SUD and who had completed various types of treatment at the VA.
These individuals were assessed through five years after treatment. The results showed
that participants had much higher abstinence rates after PTSD treatment than with SUD
treatment. These greater effects were especially pronounced during the first year after
treatment, though were maintained during the entire five year follow-up.
Integrated Treatments
Drake, Mercer-McFadden, Mueser, McHugo, and Bond (1998) define integrated
treatments as treatments that “simultaneously address two or more interwoven disorders”
(p. 590). These authors state that the benefits of integrated treatment are fewer conflicts
between treatment providers and fewer burdens on the client (i.e. transportation,
financial). Integrated treatments are believed to be more effective then single treatments
as they address both disorders simultaneously and thus have been suggested by a variety
of authors (Boudewyns et al., 1991; Kofoed, Friedman, & Peck, 1993; Najavits, Weiss, &
Shaw, 1997).
Minkoff and Cline (2004) described a model for treating co-occurring disorders
which included integrated treatments as a main characteristic. This model has eight
principles that should guide integrated services: dual diagnosis is an expectation, all
individuals with dual diagnoses are not the same, treatment relationships are highly
valued, case management is balanced with realistic expectations, both diagnoses should
be considered primary, both diagnoses can be treated in the same framework,
interventions should be individualized, and outcome assessment should also be
individualized.
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Surveys of clients’ desires for treatment have found most expressing a desire for
integrated treatment of their substance abuse and trauma symptomology (Back, Brady,
Jaanimagi, & Jackson, 2006; Brown, Stout, & Gannon-Rowley, 1998; Levan, 2006;
Najavits, Sullivan, et al., 2004). In a qualitative study by Stam (2002), women who were
dually diagnosed reported the need for integrative treatment, but that treatment of the
substance use should come first. This prioritization of the substance use was due to the
fact that the participants stated they might not have been able to cope with the process of
trauma recovery prior to abstinence.
Steindl, Young, Creamer, and Crompton (2003) found positive outcomes with
Australian veterans with PTSD undergoing concurrent, primarily cognitive behavioral,
treatment for PTSD and alcohol use. These participants were divided into low risk and
hazardous drinking groups (based on AUDIT scores). The total sample showed decreased
PTSD and drinking symptoms, though the low risk drinking group had a greater decrease
in symptoms than the high risk drinking group and unfortunately it is not known how
much changes the high risk group experienced. A study of VA treatments found that
integrated treatments had improved psychiatric symptom, employment, abstinence rate
and aftercare outcomes than non-integrated treatments (Moggi, Ouimette, Finney, &
Moos, 1999).
Cocozza et al. (2005) compared the effects of nine treatment programs that
offered integrated trauma informed treatment versus treatment as usual. Participants
(n=2006) in both treatment and comparison sites showed statistically significant
improvements on drug, alcohol, PTSD, and mental health outcomes at 6-month follow-up
with participants in the treatment as usual sites showing greater improvements. Greater
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integration of treatment showed more improvement than the treatment as usual sites or
less integrated sites. Unfortunately, this study only provided broad treatment
characteristics for the sites, which made it difficult to determine what specific kinds of
treatment were the most useful.
Seeking Safety. The Seeking Safety treatment model is the first, and currently the
most researched, manualized treatment for dual PTSD and SUD (Najavits, 2002b). The
model was first developed as a group treatment for women and based on four research
literatures: SUD, PTSD, women’s treatment, and educational research (Najavits, Weiss,
& Liese, 1996). The treatment is present-focused and focuses on helping clients learn to
cope with current life stressors. It is designed for 25 sessions but may be longer or shorter
as needed. Seeking Safety can be conducted with either gender and in either group or
individual formats, and can also be integrated into other treatments (Najavits, 2002b).
Seeking Safety has been effective with a variety of populations. The treatment has
mainly been used with women (Najavits, Weiss, Shaw, & Muenz, 1998; Young, Hills, et
al., 2004; Gatz et al., 2007; Mcnelis-Domingos, 2004). Its use has also been researched
with correctional populations (Zlotnick, Najavits, Rohsenow, & Johnson, 2003;
Hamilton, 2006), lower SES individuals (Hien, Cohen, Miele, Litt, & Capstick, 2004),
veterans (Weller, 2005; Desai, Harpaz-Rotem, Najavits, & Rosenheck, 2008), and
adolescents (Najavits, Gallop, & Weiss, 2006). While all of these studies demonstrated
Seeking Safety’s effectiveness, nearly all of them were pilot studies that lacked control
groups.
Seeking Safety has also been explored with a Revised Exposure Therapy
component (Najavits, Schmitz, Gotthardt, & Weiss, 2005). This combined therapy was a
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30-session treatment lasting five months. The five male participants demonstrated
positive results: the participants displayed perfect attendance and their PTSD and SUD
symptoms significantly decreased. They also reported less suicidal ideation. Furthermore,
the participants reported being very satisfied with the treatments.
An unpublished meta-analysis found that Seeking Safety was effective in treating
PTSD (r=.340), SUD (r=.218), and other psychological symptoms (r=.283) (Dolan,
2008). However, Seeking Safety was not statistically significantly better than a cognitivebehavioral coping skills relapse prevention therapy (Hien, Cohen, Miele et al., 2004).
Exposure-Based. Some authors suggest that exposure therapies have a place in
dual PTSD and SUD treatment (Coffey, Dansky, & Brady, 2003). One such treatment
that incorporates exposure is Concurrent Treatment of PTSD and Cocaine Dependence
(CTPCD) (Back, Dansky, Carroll, Foa, & Brady, 2001). CTPCD is a cognitivebehavioral therapy for outpatients with PTSD and cocaine dependence. The main goals
are to educate the client about the relationship between PTSD and SUD, initiate and
maintain cocaine abstinence, and decrease PTSD symptomology. The main activities to
accomplish these goals are psychoeducation, coping skills training, relapse prevention
techniques, cognitive restructuring, and in-vivo and imaginal exposure therapy. The
guidelines for the therapy note that those who have suicidal or homicidal ideation, severe
depression, vulnerability to dissociative episodes, or who can’t stand intense affect may
not be appropriate for the exposure components of the therapy. The treatment is mainly
designed for inpatient and outpatient populations, though Coffey, Schumacher, Brimo,
and Brady (2005) also describe a modification for use in community mental health
centers. Brady, Dansky, Back, Foa, and Carroll (2001) tested the effects of CTPCD with
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39 participants and found that while the participants had a high drop-out rate, the
treatment was effective in reducing PTSD and SUD symptoms for those who completed
the treatment. This last finding suggests a need for more effective engagement strategies
to reduce high drop-out rates.
Another treatment that incorporates exposure is the Substance-Dependence PTSD
Therapy (SDPT) (Triffleman, 2003; Triffleman, Carroll, & Kellogg, 1999). SDPT is an
outpatient individual therapy that is conducted twice weekly for 20 weeks. It is a
combination of cognitive-behavioral coping skills treatment for SUD, stress inoculation
training, and in-vivo exposure for PTSD. Exposure is conducted in a hierarchical manner
to allow the client to set the pace and not become overwhelmed too quickly. The manual
suggests that the treatment should be offered in conjunction with psychopharmacological
interventions. Clients with psychotic disorders or who are on the extremes of
homelessness are described as poor candidates for this approach “as the exigencies of
daily living become paramount” (Triffleman, Carroll, & Kellogg, 1999, p.8). A pilot
study of SDPT showed improvements on PTSD and SUD symptoms though SDPT was
not statistically significantly more effective than Twelve Step Facilitation treatment
(Triffleman, 2000).
A third treatment that includes an exposure based treatment is Transcend, which
is a 12-week partial hospitalization manualized treatment protocol that utilizes group
therapy to treat dual PTSD and SUD (Donovan, Padin-Rivera, & Kowaliw, 2001). The
main goals of the treatment involve reduction of PTSD symptoms, abstinence from
substances, mastery of impulsive behavior, diminishment of shame, and an increase in
self-acceptance and self-efficacy. A study of 46 combat veterans undergoing Transcend
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treatment showed statistically significant improvements on PTSD and SUD symptoms
that persisted all the way to a year after treatment completion (Donovan, Padin-Rivera, &
Kowaliw, 2001).
Other. There are a number of other integrated treatments that have been proposed
but have yet to be empirically tested. These treatments include TARGET (Ford & Russo,
2006), ATRIUM (Miller and Guidry, 2001), and unnamed treatment models proposed by
Harris (1996), Brinson and Treanor (1989), Meisler (1999), Abueg and Fairbank (1991),
Den Bleyker (2000), Evans and Sullivan (1995; Sullivan & Evans, 1996), and by Seidel,
Gusman, and Abueg (1994).
Other types of treatment address factors that the authors believe underlie both
disorders. For example, Simpson, Kaysen, et al. (2007) examined the effects of
Vipassana meditation on dual diagnosis PTSD and SUD. Vipassana meditation is a form
of meditation that stresses mindfulness, which the authors believed to be an important
component of recovery from the dual diagnosis. Participants who learned this meditation
displayed less substance use at follow-up and there also was a statistically non-significant
trend toward improvement in PTSD symptoms.
Summary
Many treatment manuals and guidelines have been developed for the treatment of
dual diagnosis SUD and PTSD. Unfortunately, large numbers of rigorous empirical
studies testing their effects have not been conducted. The studies that have been
conducted suggest that treatment, both integrated and consecutive, is effective with this
population, though it is not known which approach to treatment is more helpful. The
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effect that the presence or absence of an exposure-based component has on outcomes is
also a question that the literature has not yet adequately answered.
There are common factors linking the various types of treatment for dual
diagnosis SUD and PTSD. Nearly all of them have both psychoeducation and coping
skills components. Most also stress the importance of trust issues within the therapeutic
process and social functioning in other areas of the client’s life. Unfortunately, because
the lack of treatment fidelity measures is such a major methodological issue in this
literature, it is difficult to state for certain what those common factors are. Integrated
treatments have also generally been developed more recently, and many of these studies
were initial pilot studies that lacked adequate control or comparison groups.
Conclusions
The literature on individuals with co-occurring PTSD and SUD has focused on a
variety of questions: (a) how does the dual diagnosis develop and maintain itself, (b) how
does it present itself clinically, and (c) how best can this dual diagnosis be treated. The
literature surrounding each of these areas had strengths and weaknesses. Strengths
included the broad set of questions that have been addressed and the large number of
different therapies that have been tested with this population. Weaknesses included
questionable diagnostic procedures and lack of treatment reliability. Also, the pilot nature
of many studies meant small sample sizes and lack of a control group. Other studies
aggregated treatments and did not report enough details to determine the effectiveness of
the specific treatments.
There were also quite a few gaps in the literature that need to be filled. Questions
regarding the effectiveness of integrated treatments compared with sequential treatments
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still need to be answered. The inclusion of components such as exposure therapy also
needs to be evaluated more thoroughly. Unfortunately, the literature does not provide
clear answers to any of these questions at this time, though the answers could be of great
utility in treating individuals who seek treatment for this dual diagnosis. Therefore,
further studies should be conducted to determine if different treatment factors affect
outcomes and should include larger sample sizes that compare various types of
treatments. Components such as exposure should also be varied to test their effects.
Future research should also focus on the longitudinal course of the dual disorder.
Little is known about the etiology of the dual disorder, and more knowledge regarding
the development of the disorders would be helpful for developing new treatments and
possibly in treatment matching efforts. Furthermore, moderator variables, such as gender
or substance used, should be taken into consideration, as a few studies have found these
to be important variables (Jaycox et al., 2004; Stewart et al., 1999). The ideal study for
examining all these factors would be a longitudinal study that regularly measured PTSD
symptom clusters, SUD symptoms for a variety of substances, other psychological
symptoms such as depression and coping skills, and also measured proposed vulnerability
factors such as type of trauma. Meta-analytic techniques that combine the results in a
way that allow for structural equation modeling or logistic regression may also be
extremely useful.
Future research also needs to address the diagnostic weaknesses that have plagued
earlier studies. Questionable diagnostic procedures could be remedied by using multiple
sources of diagnostic information. For example, rather than relying on chart review, a
clinical interview and/or diagnostic instrument could also be used. Psychometric data
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should also be provided for the measurement instruments that were used. Treatment
fidelity should also be measured and assured by training and the use of second raters.
Detailed information on the treatments used should also be provided.
Finally, there is a gap in the literature regarding how symptom interplay between
the two disorders affects treatment outcomes. For example, a study by Steindl, Young,
Creamer, and Crompton (2003) with Australian veterans undergoing concurrent treatment
of PTSD and alcohol use found that early changes in alcohol use predicted later changes
in PTSD symptoms. However, the reverse was not true. Improvements on one variable
may also be found to be necessary before improvements are realized on other variables, a
finding that would have very important treatment implications. At this point, it is not
clear how treatment affects these symptom clusters and how these symptom clusters
affect each other.
Early reviews of the dual diagnosis literature called for more research (Brown &
Wolfe, 1994) and this suggestion still holds true today. The main question yet to be
answered in this area still revolves around the effectiveness of treatments for this dual
diagnosis. In spite of the evidence that this dual diagnosis is difficult to treat as well as
the many treatment models that have been proposed, there is not yet any compelling
evidence that these new treatments are any more effective than the usual treatments.
More outcome studies need to be conducted to determine the absolute and comparative
effects of these proposed treatments.
Meta-analytic techniques could also be used to compare aggregated results of
integrated versus comparative treatments. Integrated and sequential treatments could be
compared on PTSD, SUD, and other psychological outcomes to determine how effective
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they are. A meta-analysis could also examine other variables such as gender, type of
trauma, or substance of abuse to determine whether they are affecting treatment
outcomes. While meta-analytic findings would still carry the inherent weaknesses of the
underlying studies, it would provide clearer answers to questions regarding the
effectiveness of different approaches to treatment for these disorders.
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CHAPTER III
METHODS
The purpose of this dissertation was to meta-analytically examine the literature on
the effectiveness of treatment for dual diagnosis PTSD and SUD. To do this, the effects
of integrated treatments versus non-integrated treatments were compared. An exploration
of symptom interplay between the disorders was also attempted by aggregating treatment
follow-up data.
“The foundation of science is the cumulation of knowledge from the results of
many studies” (Hunter & Schmidt, 2004, p. xxvii). The results of a single study are rarely
useful in and of themselves. The replication of results greatly increases confidence in
conclusions, and so methods that combine and accumulate results across studies are
extremely valuable. One method to accomplish this is to conduct a critical review of the
literature like the one found in Chapter Two. A strength of such a review is its breadth
and the relative ease with which it can be conducted. As Hunter and Schmidt (2004)
demonstrated, however, conclusions from such a review can be based not on real
differences in the data, but instead on chance variations. Meta-analysis is another form of
knowledge accumulation that avoids many of the weaknesses of the literature review by
combining the results in a quantitative fashion.
The National Research Council (1992) noted that the reason to combine results is
that each individual study represents a “noisy reading on the underlying quality of
interest, and aggregating across them tends, under many (but not all) circumstances, to
average out the noise to at least some extent” (p. 32). The Council further stated that in
order to combine results across studies, the information sources need to be sufficiently
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similar and that the investigator is able to describe these similarities in the form of a
model or framework. The model used in this study is shown in Figure 1 and illustrates the
various paths of effect that treatments of this dual diagnosis are thought to take.
Figure 1: Dual Diagnosis Treatment Path Analysis

SUD

A

SUD Treatment

E

F

PTSD

SUD

PTSD Treatment

B

E

F

PTSD

SUD

C

Integrated
Treatment

E

D

F

PTSD

Treatment of Dual Diagnosis 36
There are two main areas of interest in this path diagram. The first area of interest
involves paths E and F. These paths represent the cyclical nature of the dual disorder as
discussed previously. These paths theoretically have positive, significant effect sizes that
represent the possibility that increases in symptoms of one disorder will lead to increases
in symptoms of the other disorder (Clark et al., 2001; Stewart & Conrod, 2003).
The second area of interest concerns the effects of treatment on the disorders.
These effects are hypothesized to be different depending on the type of treatment being
examined. SUD treatments mainly target the SUD and are thought to be effective mainly
on the SUD symptoms (path A; Back, Waldrop et al., 2006). The rationale for this
treatment is that SUD symptoms first need to be lowered to a certain threshold (i.e., so
that path E is sufficiently low) at which point the PTSD treatment is then safe and
effective for the client to engage in (Becker, Zayfert, & Anderson, 2004).
PTSD treatment, on the other hand, is thought to have a direct impact on PTSD
symptoms with a moderately large effect on reducing these symptoms (path B; Powers et
al., 2010). The effect of PTSD treatment on SUD has not been investigated as thoroughly
(perhaps because many clinicians are worried that PTSD treatment can lead to relapse;
Becker, Zayfert, & Anderson, 2004). There is also some evidence, however, that suggests
that PTSD treatment is effective in treating SUD symptoms (Ouimette, Moos, and
Finney, 2003).
Integrated treatments are believed to have an effect on both disorders. In other
words, the effects represented by paths C and D in Figure 1 would both be statistically
significant. It is believed that this type of treatment would also begin to decrease the
effects of the disorders on each other (paths E and F).
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The purpose of this study was to begin to assign quantitative values to these paths.
The effects of various forms of treatment (paths A – D) were the main focus of the study.
However, the effects of the individual disorders on each other (paths E and F) during
treatment were also secondary questions. The methodology is described in terms of the
three stages in which it took place: literature search, coding, and the statistical analysis.
These stages are analogous to gathering the data, transforming it into a usable form, and
then analyzing it.
Literature Search
A literature search was conducted to identify published empirical outcomes
studies for the treatment of dual diagnosis PTSD and SUD. The diagnosis of PTSD was
first included in the 1980 version of the DSM (i.e., the DSM-III; APA, 1980) and
consequently only studies from 1980 onwards were included. The treatment studied
needed to be psychosocial in nature as tests of the effects of medication were beyond the
scope of this study. Thus, studies that were purely exploring the effects of medication on
this dual diagnosis were not included, though it was possible that participants of
psychosocial treatment studies were also on medication to treat their symptoms. Due to
the small number of studies that have been conducted in this area, the use of less reliable
diagnostic procedures was not included as an exclusionary criterion in this study (e.g.,
diagnosis by chart review). The individuals needed current diagnoses for both SUD and
PTSD and their symptoms had to be measured on at least two time points so that a
change score correlation could be generated.
White (1994) stated that the point of a good literature search is not to track down
every paper on a subject (which would likely be impossible), but to avoid missing an
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important source outside of one’s usual searches. Therefore, a broad array of sources was
used for the current literature search including peer-reviewed journals, professional
organizations (e.g. American Psychological Association), governmental sources,
dissertations, and/or presentations. Five main literature search strategies were used to find
these sources including footnote chasing, consultation, searches in subject indexes,
browsing, and citation searches (White, 1994). Footnote chasing entailed searching
through reference sections of major reviews in the area and through journal tables of
content. The literature reviews consulted included those conducted by Ford, Russo, and
Mallon (2007); Riggs and Foa (2008); Bernhardt (2009); and McClure (2009).
Reed and Baxter (1994) discussed the importance of a comprehensive search
strategy over a broad array of databases. PsycInfo was searched using post-traumatic
stress disorder, alcoholism, drug abuse, and treatment as keywords. Medline was
searched with keywords stress disorders, posttraumatic; substance related disorders and
treatment or therapeutics. Other databases searched using combinations of PTSD and
SUD keywords were the alcohol studies database, PILOTS database, Evidence Based
Medicine Reviews, and the Substance Abuse and Mental Health Archive. Research
registers are also important to search as they may include studies that were not published
or are otherwise inaccessible (Dickersin, 1994). Thus, the National Research Register
Archive, Clinical Trials database, and the VA Cooperative Studies Programs were
consulted. Browsing included searching through the library stacks for similarly themed
books. Citation searches include the use of forward citation search engines such as Social
Sciences Citation Index for major reviews in the area. Articles used for the forward
citation search were Stewart (1996); Najavits (1997); Ouimette (1997); Zaslav (1994);
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and Jelinek and Williams (1984). The tables of content of journals that were consulted
included the Journal of Dual Diagnosis, Journal of Substance Abuse Treatment, and
Journal of Addictive Behaviors. Consultation included talking with the “invisible
college” which is other experts in the field (Rosenthal, 1994). Authors were contacted
who had published multiple studies in the area of co-occurring PTSD and SUD treatment.
Coding
Once the studies were collected, the next step was translating these data into a
useful format, a process called coding. Appendix A contains the completed coding sheets
for the included studies. Appendix B contains the definitions and decision rules for this
coding. Both of these appendices were heavily influenced by Stock’s (1994) discussion
of coding.
The first section of the coding sheet encompassed article information and was
mainly used to identify the article itself. This included the type of the article and date it
was published, even though there were no reasons to believe they would be meaningful
moderators. The next section coded was the treatment section. This section encompassed
treatment and sample information. Multiple treatments within the same study were coded
using separate coding sheets. Treatment strength and dosage were coded in terms of the
number of weeks of treatment and the number of hours per week of treatment. The
demographic variables coded included gender, race, veteran status, primary substance,
and age.
The final section coded for was the outcomes section which included the main
statistics that were used in the analysis. The correlation used for this meta-analysis was
the r statistic. The r statistic is generally viewed as the most useful correlation statistic to
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use when variables are continuous (Rosenthal, 1994). The r2 statistic was not used
because it does not express directionality and practical magnitude is likely to be
misinterpreted. The d statistic was not used in the initial coding as many studies in this
literature were pilot studies and did not include a comparison. Appendix C contains the
formulae used to convert other statistics into the r statistic. The majority of the
conversions made were derived from means and standard deviations. Other statistical
information that was coded was the name and type of each measurement instrument, as
well as their reliability coefficients. Each outcome section was repeated for multiple
measurement times. The quality of the study was not explicitly coded as some of the
artifact corrections helped account for quality (e.g., measurement reliability) and because
of the general lack of reliability in the coding of study quality (Hunter & Schmidt, 2004).
The present author was the primary coder of these data. One other individual also
coded the statistical information for these studies as a reliability check. Disagreements
were resolved through conferencing to arrive at consensus. These data were then entered
into an Excel spreadsheet for data analysis.
Orwin (1994) listed some sources of error inherent in the coding process:
deficient reporting, ambiguities in judgment process, coder bias, and coder mistakes.
Missing data is also a serious issue and takes three forms: missing studies, missing data to
estimate effect sizes, and missing characteristics of studies (Pigott, 1994). Missing
studies, such as those that were not published or accessible, were not used in this analysis
because of lack of availability. Missing data to estimate effect sizes was a minor problem
as occasionally only statistically significant results were reported, though other results
were measured. In these cases, the nonsignificant results were assumed to have an r =
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0.0. This assumption leads to conservative effect and variance estimates, though there
are few other options in dealing with missing effect sizes (Pigott, 1994). Similarly, a few
studies reported only significant results on a few subscales of an instrument. In these
cases the unreported subscale correlations were assumed to be 0.0 and the reported and
unreported scales were averaged to gain a single correlation for that measure. Missing
characteristics of studies were inferred and estimated where possible from information in
the study or from other sources (e.g., instrument reliabilities). The coding sheet and
definitions were developed to be as simple and judgment free to minimize ambiguities,
bias, and mistakes.
Statistical Analysis
This analysis used the Hunter and Schmidt (2004) model of psychometric metaanalysis. This model of meta-analysis is a set of statistical techniques that combine data
across studies while simultaneously correcting for various sources of error and bias
within these results. This model of meta-analysis is a random effects model of metaanalysis as opposed to a fixed effects model, which means that this model does not
assume homogeneity of effect sizes between studies. This type of meta-analysis has been
found to be more accurate than other models (Hunter & Schmidt, 2004). Other
researchers have noted that random effects models have the advantage of being viewed as
representative of a sample of the universe of studies on the subject, which makes them
more generalizable (Raudenbush, 1994).
There are a variety of sources of systematic error and bias that exist in studies that
are correctible in a meta-analysis. Some of the more important of these sources involve
sampling error, measurement error, and restrictions of range. The rationale behind
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correcting for these sources of error is that the purpose of a meta-analysis is to attain as
accurate of a correlation coefficient to the actual population coefficient as possible
(Hunter & Schmidt, 1994). Imperfect reliability and validity both occur when a less than
perfect instrument is used (which is all of the time in scientific experiments).
Dichotomization occurs when the participants are divided into two groups based on a
point on an otherwise continuous variable. Range restriction is only accepting a certain
subgroup of the larger population. Another source of error that must be corrected is when
multiple measures are used to assess the same variable (Gleser & Olkin, 1994). All of
these imperfections serve to lower the estimate of the correlation.
Some attempts were made to correct the less than perfect reliability in the studies
analyzed. Imperfect validity and intercorrelation between measures were not corrected
due to a lack of psychometric data. Dichotomization and range restriction were not
corrected for as they were not issues in this literature. The formulae used to correct for
these sources of error can be found in Appendix D. It should be noted that some sources
of error such as data entry cannot be corrected and remained within the effect size
approximation (Hunter and Schmidt, 2004).
Appendix E contains the formulae that were used to conduct the aggregation of
corrected data. The formula for the aggregated correlation coefficient was weighted by
two figures. The first was the sample size and the second involved the corrections that
were used for that study. These weights assigned higher priority to studies with larger
sample sizes and to studies that needed less correction (i.e., they were more accurate).
Shadish and Haddock (1994) provide three assumptions that need to be met when
deciding if and how to weigh certain studies over others: (1) theory or evidence
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suggesting that certain studies have varying degrees of accuracy, (2) the nature of this
bias can be estimated, and (3) appropriate weights can be given to compensate for the
bias. Hunter and Schmidt’s (2004) weighting method met these assumptions.
Both the observed and expected variances of these correlations were also
calculated. The observed variance was the variance of the observed correlations, while
the expected variance was calculated using a sampling error formula. As the goal of a
meta-analysis is to provide an accurate estimate of the correlation and variance, the
expected variance attributed to the sampling error was removed from the observed
variance estimate. In some cases, the expected variance was greater than or equal to the
observed variance. For these cases, the corrected variances were set to 0.0.
These two variances were also compared to determine if there was some other
source of variance that was unaccounted for. For most of the outcomes, there was a
significant difference between the two, which indicated that there could be some
uncorrected error or a moderator variable. At this point a moderator analysis was used to
determine if any of the moderators that had been previously coded (e.g., treatment type,
gender, race, dosage) served as a moderator variable.
Using these procedures, quantitative effect size correlations were assigned to the
paths of Figure 1. The model used to make these assignments involved univariate data
analysis which treated each of the paths as though they are independent of each other.
This analysis was chosen, as opposed to other types of analyses (e.g. EM method or
generalized least squares), due to its relative simplicity as well as the current state of the
literature. Most studies in this analysis provided only select correlations between
variables; as a result, the other types of analyses would be left with many omissions in
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their correlation matrices. For these reasons, a univariate data analysis was deemed to be
the best procedure for this model at the present time.
Effect sizes across treatments were compared to determine if integrated versus
consecutive treatments are more effective. For comparison of treatments, the statistic
Cohen’s d was used. Effect sizes across time were plotted to determine if reductions in
certain symptoms predicted changes in other sets of symptoms.
Clinical significance is another important consideration when attempting to
address questions regarding treatment effectiveness. Clinical significance has been
defined as the “extent to which therapy moves someone outside the range of the
dysfunctional population or within the range of the functional population” (Hageman &
Arrindell, 1999, pp. 1169-1170). The use of clinical significance allows the classification
of clients undergoing treatment into those who are unchanged or deteriorated, those who
are improved but not recovered, and those who have recovered. Within the context of a
meta-analysis, Hageman and Arrindell (1999) suggest estimating the proportion of clients
experiencing positive change versus those that did not experience positive change as a
means of calculating clinical significance. To this end, a binomial effect size display was
employed.
The final step was a publication bias analysis (Begg, 1994). Publication bias
exists when only certain studies get published. These published studies are theorized to
be the ones that have higher effect sizes, which then leads to an upward bias in metaanalytic results. One method to avoid this biased sampling frame is to include as many
studies as possible. For this reason a comprehensive literature search strategy was used.
To test for the presence of publication bias, a funnel graph was used. A funnel graph plots
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effect size against sample size and if no publication bias is present then this graph should
look like a funnel in which smaller sample size studies have a greater spread of
correlations and higher sample size are more narrowly concentrated around the midpoint.
Hunter and Schmidt’s (2004) file drawer analysis based on effect size was used to
determine how many studies averaging null results would be needed to bring the
observed correlations down to a predetermined critical value.
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CHAPTER IV
RESULTS
The initial literature search yielded 124 studies that discussed treatment for dual
diagnosis for SUD and PTSD. After closer inspection of these studies, seventeen of these
were found to meet the inclusion criteria set for this study. One report was excluded as it
was a case study. Four were excluded as they were primarily medication studies. Fortysix studies were excluded because they did not include statistics necessary for this metaanalysis (e.g., no pre-post measurements). Another forty-four were excluded because the
sample population did not meet the inclusion criteria of this meta-analysis (e.g., SUD and
trauma, but not necessarily PTSD). Seven studies were excluded because the data
reported was used in other studies that were included in this analysis. Five studies were
not included as they could not be obtained by the primary author. These studies were
requested through interlibrary loan and by contacting the primary authors when contact
information was available, but were still not attained. Characteristics of those studies that
were included in this analysis can be found in Table 1. These studies yielded 101
individual correlations that were then used in the meta-analysis.
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Table 1
Study Characteristics
Study
Back, Jackson,
Sonne, Brady,
2005
Brady, Dansky,
Back, Foa,
Carroll, 2001

Treatment
CB coping
skills therapy
for SUD
Integrated
CTCPD

Brown, 2000

Inpatient SUD

Brown, Read,
Kahler, 2003

Inpatient SUD

Coffey,
Schumacher,
Brady, Cotton,
2007
Cook, Walser,
Kane, Ruzek,
Woody, 2006

In and
outpatient SUD

Integrated
Seeking Safety

Outcomes Measured
Post PTSD total
Post SUD ETOH

O r N n
.64
86
.50
86

Post PTSD total
Post PTSD re-experiencing
Post PTSD arousal
Post PTSD avoidance
Post SUD Drug
Post SUD ETOH
Post General psych
6 month PTSD total
6 month PTSD reexperiencing
6 month PTSD arousal
6 month PTSD avoidance
6 month SUD Drug
6 month SUD ETOH
6 month General psych
6 month PTSD total
6 month Drug & ETOH
6 month PTSD total
6 month SUD Drug & ETOH
6 month General psych
Post PTSD total
Post PTSD re-experiencing
Post PTSD arousal
Post PTSD avoidance
Post PTSD total

.49
.44
.37
.45
.62
.38
.38
.61
.28

15
15
15
15
15
15
15
7
7

.61
.56
.71
.55
.92
.43
.62
.46
.56
.56
.19
-.01
.13
.20
.52

7
7
7
7
7
29
29
52
52
52
45
45
45
45
18
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Study
Donovan, PadinRivera, Kowaliw,
2001

McGovern,
Lambert-Harris,
Acquilano, Xie,
Alterman, Weiss,
2009

Treatment
Integrated
Transcend

Integrated CBT
for PTSD

Najavits, Harned,
Gallop, Butler,
Barber, Thase,
Crits-Cristoph,
2007

Various SUD

Najavits, Gallop,
Weiss, 2006

Integrated
Seeking Safety

Najavits, Gallop,
Weiss, 2006
(same as previous
article)

Non-integrated
treatment as
usual

Outcomes Measured
Post PTSD total
Post PTSD re-experiencing
Post PTSD arousal
Post PTSD avoidance
6 month PTSD total
6 month PTSD reexperiencing
6 month PTSD arousal
6 month PTSD avoidance
6 month SUD Drug
6 month SUD ETOH
1 year PTSD total
1 year PTSD re-experiencing
1 year PTSD arousal
1 year PTSD avoidance
1 year SUD Drug
1 year SUD ETOH
Post PTSD total
Post PTSD re-experiencing
Post PTSD arousal
Post PTSD avoidance
Post SUD Drug
Post SUD ETOH
3 month PTSD total
3 month PTSD reexperiencing
3 month PTSD arousal
3 month PTSD avoidance
3 month SUD Drug
3 month SUD ETOH
3 month SUD Drug
3 month SUD ETOH
6 month SUD Drug
6 month SUD ETOH
3 month General psych
6 month General psych
Post SUD Drug & ETOH
Post General psych
3 month SUD Drug & ETOH
3 month General psych
Post SUD Drug & ETOH
Post General psych
3 month SUD Drug & ETOH
3 month General psych

r N n
.32
46
.21
46
.25
46
.30
46
.29
46
.26
46
.21
.27
.35
.40
.30
.23
.17
.33
.33
.40
.80
.74
.58
.76
.23
.41
.86
.77

46
46
46
46
46
46
46
46
46
46
11
11
11
11
11
11
10
10

.66
.84
.29
.27
.63
.19
.65
.10
.09
.16
.55
.12
.17
-.18
.18
.01
.33
.10

10
10
10
10
34
34
34
34
34
34
18
18
18
18
15
15
15
15
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Study
Najavits, Schmitz,
Gotthardt, Weiss,
2005
Najavits, Weiss,
Shaw, Muenz,
1998

Norman, Wilkins,
Tapert, Lang,
Najavits, n.d.

Treatment
Integrated
Seeking Safety
with exposure
treatment
Integrated
Seeking Safety

Integrated
Seeking Safety

Ouimette, Ahrens, Various SUD
Moos, Finney,
1997
Ouimette, Ahrens, Inpatient SUD
Moos, Finney,
1998
Ouimette, Finney, Various SUD
Moos, 1999
Zlotnick,
Najavits,
Rohsenow,
Johnson, 2003

Integrated
Seeking Safety

Outcomes Measured
Post PTSD total
POST SUD Drug
Post General psych

r
.85
.81
.09

n
5
5
5

Post PTSD Total
Post SUD Drug
Post SUD ETOH
Post General psych
3 month PTSD total
3 month SUD Drug
3 month SUD ETOH
3 month General psych
Post PTSD total
Post SUD ETOH
Post General psych
3 month PTSD total
3 month SUD ETOH
3 month General psych
6 month PTSD total
6 month SUD ETOH
6 month General psych
1 year SUD Drug
1 year SUD ETOH
1 year General psych
Post General psych

.00
.26
.00
.00
.28
.20
.00
.00
.31
.22
.41
.75
.49
.74
.55
.55
.19
.29
.31
.06
.46

11
11
11
11
11
11
11
11
9
9
9
4
4
4
4
4
4
140
140
140
140

2 year SUD Drug
2 year SUD ETOH
2 year General psych
Post PTSD total
Post SUD Drug
Post SUD ETOH
3 month PTSD total
3 month SUD Drug
3 month SUD ETOH

.30
.32
.09
.69
.00
.00
.52
.78
.81

135
135
135
17
17
17
15
15
15

These correlations were divided into seven different symptom categories: PTSD
total, PTSD arousal, PTSD avoidance, PTSD re-experiencing, SUD alcohol, SUD other
drugs, and other psychological symptoms. These categories were also divided into
measurement time to analyze treatment effects over time. These divisions were
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immediately post-treatment and three months, six months, twelve months, and twentyfour months post-treatment.
Treatment effects
The first research question dealt with the absolute effectiveness of treatment on
dual diagnosis PTSD and SUD. For this question, only immediate post-treatment means
were used. The mean treatment effects for PTSD total symptoms was r = .46 (SD = .14,
95% CI = .38 - .54, n = 292, N = 11), for PTSD arousal symptoms was r = .25 (SD = 0.0,
n = 117, N = 4), for PTSD avoidance symptoms was r = .32 (SD = 0.0, n = 91, N = 4), for
PTSD re-experiencing symptoms was r = .20 (SD = .14, 95% CI = .07 - .34, n = 117, N =
4), for SUD alcohol symptoms was r = .40 (SD = .09, 95% CI = .34 - .46, n = 211, N =
9), for SUD drug symptoms was r = .46 (SD = .13, 95% CI = .37 - .54, n = 155, N = 9),
and other psychological symptoms was r = .36 (SD = .39, 95% CI = .08 - .65, n = 213, N
= 7). Some corrected standard deviations were found to be 0.0, which precluded the
computation of confidence intervals. As can be seen from the confidence intervals, all of
these effects were statistically significant, which suggests that treatment for this dual
diagnosis is effective at reducing symptoms for PTSD, SUD, and other general
psychological symptoms. Stem and leaf plots for these analyses are displayed in Figure 2.
Binomial effect size displays that show clinical significance can be found in Figure 3.
These displays show the percentage of participants who had shown positive change after
treatment.
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Figure 2: Stem and leaf displays of corrected treatment effect correlations
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Figure 3: Percentage of participants with improvement after treatment
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Sequential vs. Integrated Treatments
The second research question dealt with the question of the difference between
sequential and integrated treatments. Post-treatment means were exclusively used for this
analysis (not follow-up means). Most of the treatment effect sizes were derived from
integrated treatments (N=34) while the remaining were from SUD-focused treatments
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(N=14). Integrated and SUD focused treatment statistics can be found in Table 2. Positive
d statistics represent better results for SUD-focused treatments. SUD-focused treatments
displayed significantly better results for SUD alcohol symptoms and non-significantly
better results for PTSD total symptoms, SUD drug symptoms, and other symptoms. The
only symptoms clusters that integrated treatments showed better results were PTSD
arousal, PTSD avoidance symptoms, and PTSD re-experiencing symptoms, though the
inability to compute confidence intervals due to variances = 0.0 precluded the ability to
assess statistical significance. The symptom clusters showed better results than the PTSD
total symptoms because only the least effective SUD treatment studies contributed effect
sizes to the individual symptom cluster analysis. The path model with attached effect
sizes can be found in Figure 4. Treatment effects for the SUD path were attained by
computing the mean effect size of SUD alcohol and SUD drug symptoms. The PTSD
treatment model was dropped due to the lack of studies on PTSD-only treatment with this
dual diagnosis population that met the inclusion criteria.
Table 2
Integrated vs. SUD-focused Treatments
Symptom

Treatment

PTSD total

r

SD

95% CI

N

d

SUD-focused .47

.16

.29 - .66

3

.20

Integrated

.45

.09

.39 - .51

8

PTSD

SUD-focused .13

0.0

-

1

arousal

Integrated

.33

0.0

-

3

PTSD

SUD-focused .20

0.0

-

1

avoidance

Integrated

0.0

-

3

.40

-
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Symptom

Treatment

SD

95% CI

N

d

PTSD re-

SUD-focused -.01

0.0

-

1

-8.25

.34

.06

.27 - .40

3

SUD

SUD-focused .49

.04

.44 – .53

3

alcohol

Integrated

.27

0.0

-

6

SUD drug

SUD-focused .54

.10

.42 – .66

3

Integrated

.37

.07

.31 - .43

6

SUD-focused .42

.19

.16 – .68

2

Integrated

.37

-.11 - .53

5

experiencing Integrated

Other

r

.21

11.67

2.42

.73

Note. Some confidence intervals and d statistics could not be calculated due to SD = 0
Figure 4: Dual Diagnosis Treatment Path Analysis
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Moderator Variables
The third research question focused on whether there were any other moderating
influences on treatment outcomes. To address this question, Hunter and Schmidt’s (2004)
“75% rule” was used. This criterion compares the observed variance to the variance that
would be expected given the average correlation and number of studies to determine how
much of the variance was accounted for through artifact and sampling error. If the
expected variance accounts for at least 75% of the observed variance, then it is concluded
that there are no other moderating variables as the remaining variance is assumed to be
due to unaccounted for artifact error. According to Hunter and Schmidt (2004), this
method has better or equal power in determining if there was a moderator than other
methods, a finding that applied especially when the number of studies in the metaanalysis was small, which was this case with the present analysis.
Most of the symptom clusters post-treatment failed the 75% rule suggesting that
other moderating influences were involved: total PTSD symptoms (56.4% of the variance
accounted for), SUD drug symptoms (68.5% of the variance accounted for), other
symptoms (14.6% of the variance accounted for), and PTSD re-experiencing (62.9% of
the variance accounted for). PTSD avoidance symptoms (100% of the variance accounted
for), PTSD arousal symptoms (100% of the variance accounted for), SUD alcohol
symptoms (79.4% of the variance accounted for) did not appear to be influenced by any
moderators.
Thus, a moderator analysis was conducted using the following moderators: article
date, exposure component, number of study participants, treatment dosage (measured by
total treatment hours where available), age of participants, gender of participants, race of
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participants, and type of substance use disorder (dependence or abuse). None of the
coded variables were found to be clear moderators for PTSD total symptoms. The
number of subjects in a study was found to moderate the effects on SUD drug symptoms
with low n studies (less than 20 participants) having a mean r = .34 (SD = 0) and high n
studies having a mean r = .63 (SD=0) and on PTSD re-experiencing symptoms with low
n studies having a mean r = .57 (SD = 0) and high n studies having a mean r = .10
(SD=0). Other symptoms appeared to be moderated by the racial composition of the
participants as studies with higher proportions of racial minorities (one third or more of
the sample) having a mean of r = .06 (SD=0) and lower proportions having a mean of r =
.45 (SD=0). Caution should be taken when interpreting these results, especially given the
contradictory findings regarding how the number of participants moderates the results.
Treatment over time
The fourth research question dealt with the effectiveness of treatment over time
with individuals with dual PTSD and SUD. Treatment over time effects can be found in
Figure 5. Some of these follow-up data were based on studies that also presented
immediate post-treatment effects (e.g. Donovan, Padin-Rivera, Kowaliw, 2001) while
others presented only follow-up data (e.g. Brown, Read, Kahler, 2003). A few studies
presented serial data using the same participants over time. For example, Ouimette,
Ahrens, Moos, and Finney (1997) presented one-year follow-up data and Ouimette,
Finney, and Moos (1999) presented two-year data for the same participants.
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Figure 5: Treatment over time mean correlation effects
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Total PTSD symptoms showed a relatively large effect initially with r = .46 (SD =
.14, 95% CI = .38 - .54, n = 292, N = 11) and a slow linear decrease after a year (r =.30,
SD = 0, n = 46, N = 1). All three PTSD symptom clusters showed similar trajectories.
After 3 months, each symptom cluster showed a large increase in effect size. This
increase was due to the effect size coming from a single study and is thus not reflective of
a true 3-month post-treatment decrease in symptoms. After this increase in effect size,
each of the symptom clusters displayed a relatively consistent effect to what was seen
initially post-treatment.
The SUD symptoms showed medium effect sizes initially: for alcohol symptoms,
r = .40 (SD = .09, 95% CI = .34 - .46, n = 211, N = 9) and for drug symptoms, r = .46
(SD = .13, 95% CI = .37 - .54, n = 155, N = 9). These effects were relatively stable even
after two years with alcohol symptoms increasing slightly (r = .31, SD = 0, n = 135, N =
1) and drug symptoms increasing the same amount (r = .30, SD = 0, n = 135, N = 1).

Treatment of Dual Diagnosis 61
Other psychological symptoms were much more inconsistent. Post-treatment effect size
was r = .36 (SD = .39, 95% CI = .08 - .65, n = 213, N = 7). This effect was nearly erased
after three months (r = .05, SD = 0.0, n = 82, N = 5) though returned after six months (r
= .27, SD = .08, 95% CI = .19 - .34, n = 97, N = 4). One year and two year measurements
were then negligible: at one-year, r = .06 (SD = 0, n = 140, N = 1) and at two years, r =
.09 (SD = 0, n = 135, N = 1).
There was no evidence of interplay between the symptoms. Both PTSD and SUD
symptoms showed initial gains with slow decreases over time. There were no indications
from the data or graphs that either of these symptoms was affecting the other.
Publication bias
The final step of this meta-analysis entailed determining whether there was a
publication bias in the studies included in the analysis. A funnel graph with all of the
study correlations is found in Figure 6. A funnel plot theoretically should be symmetrical
with effect sizes clustered around the true effect size. Studies with low numbers of
participants should have more sampling error and thus be more spread out near the
bottom of the plot, producing the shape of a funnel. As can be seen from Figure 6, there
is a slight asymmetry to the right. Asymmetry is generally indicative of publication bias
as it suggests that studies with smaller effect sizes are not being published. It may also be
due to a third factor that relates the sample size to the size of effect. For example, smaller
sample size studies may be more prone to error or have more intense treatment, leading to
exaggerated effect sizes (Sutton, 2009). The results of this analysis are suggestive, but not
entirely diagnostic of publication bias, and these results consequently may represent an
over-estimate of the true population effect size.
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As these results suggested the presence of the “file drawer problem,” Hunter and
Schmidt’s file drawer analysis based on effect size was used to determine how many
studies with null results would need to be found to bring the observed correlations down
to a predetermined critical value. For this analysis, the critical value chosen was r=.10 as
this value would be considered a weak result and many of the observed correlations were
in the medium to strong range. The number of null result studies needed to decrease these
results to a weak level for PTSD total symptoms was 40, PTSD arousal was 6, PTSD
avoidance was 9, PTSD re-experiencing was 4, SUD alcohol was 27, SUD drug was 33,
and other psychological symptoms was 19. Therefore, while there may be a publication
bias leading to an over-estimate of effect sizes, it is likely that this bias would not greatly
weaken these results as the number of studies with null results would need to be about
three times the number of studies that were actually found measuring PTSD total, SUD
alcohol, SUD drug, and other psychological symptoms, while there would need to be
about two times the number of studies measuring the individual PTSD symptom clusters.
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Figure 6. Publication bias funnel graph
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CHAPTER V
DISCUSSION
Major Findings
The meta-analysis conducted in this study set out to answer four main questions.
The first of these questions focused on the effectiveness of treatment for this dual
diagnosis. Post-treatments effects were all statistically non-zero. Wampold (2000)
reported that the best point estimate for the effectiveness of psychotherapy compared to a
control group was d = .80, which converts to r = .37. The effective sizes in the present
study (r = .46 for PTSD symptoms and SUD drug symptoms, r = .40 for SUD alcohol
symptoms, and r = .36 for other psychological symptoms) are either larger or similar to
Wampold’s point estimate for the effectiveness of psychotherapy in general, though it
should be noted that the present findings compare pre- to post-treatment changes rather
than treatment to control groups. While some literature has described this population as
difficult to treat, (e.g., Najavits, 2002a) these findings suggest that treatment is as
effective with this population as it is with others.
The second question compared various kinds of treatment on PTSD and SUD
symptoms. SUD-focused treatments were more effective than integrated treatments for
treating SUD symptoms with d = 11.67 for alcohol use symptoms and d = 2.42 for drug
use symptoms. SUD-focused treatments were also more effective for treating other
psychological symptoms with d = .73 and total PTSD symptoms:d =.20. The only
symptoms that were decreased more in integrated treatments than in SUD-focused
treatments were the individual PTSD symptom clusters which appeared to result from
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having only the least effective SUD treatment studies contribute effect sizes to that
analysis.
These results were not expected as they contradicted the literature that suggested
that integrated treatments should display greater effects than singular treatments
(Boudewyns et al., 1991; Kofoed, Friedman, & Peck, 1993; Najavits, Weiss, & Shaw,
1997). While it might not be surprising that SUD-focused treatments had greater effects
on SUD symptoms, it is surprising that there was little difference in PTSD effects. It is
possible that this is due to SUD symptoms being the main driver of symptomology for
this dual diagnosis and focusing mainly on the SUD decreases symptoms across the dual
diagnosis. It is also possible that while SUD-focused treatments are ostensibly focused on
SUD symptoms, PTSD symptoms are also being addressed by the therapist either
explicitly or implicitly. Further research would need to be done regarding symptom
interplay and treatment factors to determine if either of these possibilities apply. These
findings do suggest caution, however, in embracing newer integrated treatments over
more established SUD-focused therapies. Integrated treatments are not contraindicated as
they showed positive effects in the present study, but more research would need to be
done to show that they are more effective than singularly focused treatments.
The third research question focused on possible moderating influences on the
treatment effect sizes. This analysis found that the number of participants moderated two
of the symptom clusters, though the direction of moderation was inconsistent with larger
numbers of participants leading to better results for SUD drug symptoms, but weaker
results for PTSD re-experiencing. Hunter and Schmidt (2004) caution against the use of
exploratory moderator analyses, especially with small numbers of studies, and the
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inconsistency of these results suggests that they may be spurious. The moderator analysis
also found that race of participants may be a moderating influence for other
psychological symptoms. While there is reason to believe that treatments can have
differing effects on different populations (Chambless et al., 1996), this result should be
interpreted cautiously due to the aforementioned low number of studies and inconsistency
of results.
The fourth research question explored treatment over time effects. The major
symptom clusters of this dual diagnosis (i.e., total PTSD symptoms, drug SUD
symptoms, and alcohol SUD symptoms) all displayed relatively stable effect sizes over
time. These effects only decreased slightly up to two years post-treatment. The other
symptom clusters showed much more variable patterns. The PTSD symptom clusters
showed a sudden leap in effectiveness at three months, but this was due to the single
study that contributed an effect size at that time point. The relative variability of other
psychological symptoms over time was puzzling as more effect sizes were involved in
that analysis, though the broad range of symptoms included in this category may have
contributed to the variability. More research would need to be done measuring these
symptoms with this population to achieve more stable results. The relative stability with
only minor decreases over time was a positive result. Further research could be done on
the effectiveness of “booster” sessions after treatment to determine if even these minor
decreases could be avoided.
One of the questions that the treatment over time analysis was intended to shed
light on was a question of symptom interplay. It was hoped that there might be some
evidence of one symptom showing a consistent improvement prior to the other; but that
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was not found to be the case. This does not necessarily preclude the possibility that one
of the symptoms tends to drive the other, as is hypothesized by the self-medication
hypothesis and similar theories. It is possible that this symptom interplay is still taking
place, but the measurement times used in this study (e.g., at post-treatment, 3-months,
etc.) were not precise enough to find it.
Generalizability of Results
This meta-analysis utilized a random-effects model of analysis, which means that
inferences to similar treatments can be made. Thus, these results can be thought to apply
to individuals with dual diagnosis PTSD and SUD who are undergoing either SUDfocused or integrated treatments for these issues. Only a third (three out of nine) of the
integrated treatments were non-Seeking Safety treatments. Thus, the low numbers of nonSeeking Safety treatments limits the ability to generalize to those other treatments. Also,
because there were no studies in the analysis that utilized PTSD-focused therapy, these
results cannot be applied to individuals undergoing that type of therapy for this dual
diagnosis. Only a single study examined the effects of treatment with an adolescent
sample, which decreases the ability to apply these results to a non-adult population.
Limitations and Guidelines for Future Research
The small number of studies included in the meta-analysis was the most serious of
the limitations of the current study. A meta-analysis depends on having a strong base of
literature to provide reliable aggregated results from which reliable conclusions can be
drawn. In the present analysis, 17 studies resulting in 101 effect sizes were found, which
would usually be an adequate number of effect sizes, but when these studies were further
subdivided by symptom and measurement time, they yielded inadequate numbers for
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some of the analyses. Specifically, the moderator analyses found contradictory results,
which may have been due to the lack of stability and low number of studies. This
weakness will decrease as more research continues to be done on the topic. Future
research publications should also include all the study results, whether significant or not.
It was apparent in some articles gathered for this analysis that data had been gathered, but
it was not reported due to statistical non-significance or for other unknown reasons. The
missing data analysis also suggested that the “file drawer” problem in which nonsignificant results are not being reported appears to be an issue in this literature.
Another limitation involved the lack of information on treatment adherence on the
part of treatment providers. This meta-analysis made a variety of comparisons between
different types of treatment and lack of treatment adherence information sheds some
doubt on the results. For example, if some of the SUD-focused treatments did include
aspects of PTSD treatment, they should have been coded as integrated in the present
study, which would have likely led to different results and conclusions.
Similarly, the lack of diagnostic certainty was an issue in some studies. For
example, some of the studies used past diagnoses of SUD and/or PTSD as diagnostic
criteria. Further information on the reliability of these past diagnoses would have been
helpful in assuring that this analysis only included individuals who met the inclusion
criteria.
As mentioned earlier, another weakness of this study was that it was ill-equipped
to explore the interplay between SUD and PTSD symptoms. To explore this issue, future
studies would need to use much more frequent outcome measurement, ideally conducted
on at least a weekly basis. Unfortunately, at present there are no studies to this author’s
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knowledge that have used this type of frequent outcome measurement, and so this issue
cannot be explored using meta-analysis, though this knowledge could be a great aid in
designing treatments for this dual diagnosis.
Another weakness to this study was that portions of the analysis were conducted
solely by the primary author. The effect sizes and the statistical components of the
analysis were double-checked by a second individual and any differences were resolved
through consensus. However, much of the work in study selection was done by a single
individual and the resulting lack of “quality checks” in this phase of data collection may
have possibly led to some form of systematic bias in study inclusion or exclusion. It
would have been preferable to use a team of researchers to conduct all phases of the data
collection and analysis in the present study.
Conclusion
The symptoms and other issues experienced by those with the dual diagnosis of
PTSD and SUD have profound effects on the lives of these individuals. The present study
aggregated the results from several studies that examined how best to help these
individuals. While this analysis found encouraging results showing that treatment is
helpful in reducing symptoms in this population, the lack of stability in those results was
also disheartening. In addition, no evidence was found for any increased efficacy of the
newer integrated treatments for this dual diagnosis over SUD-only focused treatments.
These issues need more research examination, and more efforts are needed to develop
new treatments that will be more effective with this population. Future research into
these issues will be very helpful to the many individuals who suffer from SUD and PTSD
dual diagnosis for finding the help that they need.
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Appendix A: Completed Coding Worksheets

Article Information
Article ID: 1 Title: Changes in PTSD symptomatology during acute and protracted
alcohol and cocaine abstinence
Authors: Coffey, S. F., Schumacher, J. A., Brady, K. T., & Cotton, B. D.
Type of article:1

Date: 2007

Treatment (Independent Variable)
Type of Treatment: 2 Treatment Subtype: 77% op; 23% ip + op
Treatment Dosage: 4w

Exposure: 0

Weekly Dosage: n/a

Demographics of Sample
Age: 33.6 Female%: 52 Caucasian%: n/a African-American%: n/a
Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: n/a
%Vets: n/a

Primary Substance(s): 30% cocaine; 23% ETOH; 47% both

SUD Type: D Trauma Type: multiple

Dropout%: 20

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .19

Sample Size: 45

Measurement Instrument: MPSS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: -.01

Sample Size: 45

Measurement Instrument: MPSS
Instrument Reliability: n/a

Measurement Time: post

Measurement Type: 1
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Hyperarousal PTSD symptoms
Observed Correlation: .13

Sample Size: 45

Measurement Instrument: MPSS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .20

Sample Size: 45

Measurement Instrument: MPSS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD drug symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Other symptoms
Observed Correlation: n/a
Measurement Instrument:
Instrument Reliability:

Sample Size:

Measurement Time:

Measurement Type:
What measured:
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Article Information
Article ID: 2

Title: During treatment changes in substance abuse patients with

posttraumatic stress disorder
Authors: Ouimette, P. C., Ahrens, C., Moos, R. H., Finney, J. W.
Type of article: 1

Date: 1998

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: ip

Treatment Dosage: 4w

Weekly Dosage: n/a

Exposure: 0

Demographics of Sample
Age: 44.93

Female%: 0

Caucasian%: 55.5 African-American%: 44.5

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: 100
SUD Type: A

Primary Substance(s): 53.6 ETOH; 18.6 drugs; 27.9 both
Trauma Type: n/a (majority assumed combat Dropout%: 5.7

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms

Measurement Time:
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Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD drug symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Other symptoms
Observed Correlation: .46

Sample Size: 140

Measurement Instrument: BSI

Measurement Time: post

Measurement Type: 1

Instrument Reliability: .94 What measured: general psych symptoms

Treatment of Dual Diagnosis 111
Article Information
Article ID: 6

Title: Six-month treatment outcomes of cocaine-dependent patients

with and without PTSD in a multisite national trial
Authors: Najavits, L. M., Harned M. S., Gallop, R. J., Butler, S. F., Barber, J. P., Thase,
M. E., Crits-Christoph, P.

Type of article: 1

Date: 2007

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: various

Treatment Dosage: 6m

Exposure: 0

Weekly Dosage: various

Demographics of Sample
Age: 32.71

Female%: 47.1 Caucasian%: 55.9 African-American%: 41.2

Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: 2.9
%Vets: n/a

Primary Substance(s): 100 cocaine; 44.1 ETOH; 2.9 cannibis; 2.9
sedatives

SUD Type: D

Trauma Type: various

Dropout%: 76.5

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:

Measurement Time:
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Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .19

Sample Size: 34

Measurement Time: 3m

Measurement Instrument: ASI ETOH Measurement Type: 1
Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .10

Sample Size: 34

Measurement Time: 6m

Measurement Instrument: ASI ETOH Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .63

Sample Size: 34

Measurement Time: 3m

Measurement Instrument: ASI Drug Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .65

Sample Size: 34

Measurement Instrument: ASI drug

Measurement Time: 6m

Measurement Type: 1
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Instrument Reliability: n/a
Other symptoms
Observed Correlation: .09

Sample Size: 34

Measurement Instrument: BSI

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a What measured: general psych symptoms
Other symptoms
Observed Correlation: .16

Sample Size: 34

Measurement Instrument: BSI
Instrument Reliability: n/a

Measurement Time: 6m

Measurement Type: 1

What measured: general psych symptoms
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Article Information
Article ID: 7

Title: Posttraumatic stress disorder in substance abuse patients:

relationship to 1-year posttreatment outcomes
Authors: Ouimette, P. C., Ahrens, C., Moos, R. H., Finney, J. W.
Type of article: 1

Date: 1997

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: various

Treatment Dosage: 3-4w

Exposure: 0

Weekly Dosage: n/a

Demographics of Sample
Age: 44.88

Female%: 0

Caucasian%: 57.9 African-American%: 42.1

Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: n/a
%Vets: 100
SUD Type: A

Primary Substance(s): n/a
Trauma Type: n/a

Dropout%: 12

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms

Measurement Time:
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Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .31

Sample Size: 140

Measurement Time: 1y

Measurement Instrument: Alcohol consumption via Health & Daily Living Form
Measurement Type: 1 Instrument Reliability:n/a
SUD drug symptoms
Observed Correlation: .29

Sample Size: 140

Measurement Time: 1y

Measurement Instrument: Problems from Substance Use Scale
Measurement Type: 1 Instrument Reliability:n/a
Other symptoms
Observed Correlation: .06

Sample Size: 140

Measurement Instrument: BSI

Measurement Time: 1y

Measurement Type: 1

Instrument Reliability: .94 What measured: general psych symptoms
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Article Information
Article ID: 8 Title: Two-year posttreatment functioning and coping of substance abuse
patients with posttraumatic stress disorder
Authors: Ouimette, P. C., Finney, J. W., Moos, R. H. Type of article: 1

Date: 1999

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: various

Treatment Dosage: 3-4w

Exposure: 0

Weekly Dosage: n/a

Demographics of Sample
Age: 42.83

Female%: 0

Caucasian%: 57 African-American%: 43

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: 100
SUD Type: A

Primary Substance(s): 52.1 ETOH; 20 drug; 28.9 both
Trauma Type: n/a

Dropout%: n/a

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:
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Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .32

Sample Size: 135

Measurement Time: 2y

Measurement Instrument: Alcohol consumption via Health & Daily Living Form
Measurement Type: 1 Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .30

Sample Size: 135

Measurement Time: 2y

Measurement Instrument: Problems from Substance Use Scale
Measurement Type: 1 Instrument Reliability: n/a
Other symptoms
Observed Correlation: .09

Sample Size: 135

Measurement Time: 2y

Measurement Instrument: BSI Measurement Type: 1
Instrument Reliability: .94 What measured: general psych symptoms
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Article Information
Article ID: 11

Title: A cognitive behavioral therapy for co-occuring substance use

and posttraumatic stress disorders
Authors: McGovern, M. P., Lambert-Harris, Chantel, Acquilano, S., Xie, H., Alterman,
A. I. Weiss, R. D.

Type of article: 1

Date: 2009

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: CBT for PTSD Exposure: 0

Treatment Dosage: 4-6w

Weekly Dosage: 9-12h

Demographics of Sample
Age: 34

Female%: 91

Caucasian%: 100 African-American%: 0

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: n/a

Primary Substance(s): n/a

SUD Type: n/a

Trauma Type: n/a

Dropout%: 9

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .80

Sample Size: 11

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .86

Sample Size: 10

Measurement Instrument: CAPS
Instrument Reliability: n/a
Re-experiencing PTSD symptoms

Measurement Time: 3m

Measurement Type: 1
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Observed Correlation: .74

Sample Size: 11

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: .77

Sample Size: 10

Measurement Instrument: CAPS

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .58

Sample Size: 11

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .66

Sample Size: 10

Measurement Instrument: CAPS

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .76

Sample Size: 11

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .84

Sample Size: 10

Measurement Instrument: CAPS
Instrument Reliability: n/a

Measurement Time: 3m

Measurement Type: 1
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SUD alcohol symptoms
Observed Correlation: .41

Sample Size: 11

Measurement Time: post

Measurement Instrument: TLFB + ASI ETOH Measurement Type: 1
Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .42

Sample Size: 10

Measurement Time: 3m

Measurement Instrument: TLFB + ASI ETOH Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .23

Sample Size: 11

Measurement Time: post

Measurement Instrument: TLFB +ASI drug Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .25

Sample Size: 10

Measurement Time: 3m

Measurement Instrument: TLFB +ASI drug Measurement Type: 1
Instrument Reliability: n/a
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 12

Title: Alcohol dependence and posttraumatic stress disorder:

differences in clinical presentation and response to cognitive-behavioral therapy by order
of onset
Authors: Back, S. E., Jackson, J. L, Sonne, S., Brady, K. T.
Type of article: 1

Date: 2005

Treatment (Independent Variable)
Type of Treatment: 2
Exposure: 0

Treatment Subtype: CB Coping Skills Therapy

Treatment Dosage: 12w

Weekly Dosage: n/a

Demographics of Sample
Age: 36.62

Female%: 48 Caucasian%: 85.1 African-American%: 11.7

Asian American%: 0 Latino%: 1.1 American Indian%: 2.1 Other%: 0
%Vets: n/a
SUD Type: D

Primary Substance(s): ETOH
Trauma Type: n/a

Dropout%: 34.9

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .64

Sample Size: 86

Measurement Time: post

Measurement Instrument: IES, MISS, CAPS Measurement Type: 1
Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:

Measurement Time:
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Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .50

Sample Size: 86

Measurement Instrument: TLFB

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 15

Title: Dissemination and feasibility of a cognitive-behavioral

treatment for substance use disorders and posttraumatic stress disorder in the veterans
administration
Authors: Cook, J. M., Walser, R.D., Kane, V., Ruzek, J. I., Woody, G.
Type of article: 1

Date: 2008

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety Exposure: 0

Treatment Dosage: n/a

Weekly Dosage: n/a

Demographics of Sample
Age: 50

Female%: 28 Caucasian%: n/a African-American%: n/a

Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: n/a
%Vets:100
SUD Type: A

Primary Substance(s): 78 ETOH, 61cocaine, 33 heroin
Trauma Type: n/a

Dropout%: 28

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .52

Sample Size: 18

Measurement Instrument: PCL-Military

Measurement Time: post

Measurement Type: 1

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:

Measurement Time:
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Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD drug symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 16

Title: “Transcend”: initial outcomes from a posttraumatic stress

disorder/substance abuse treatment program
Authors: Donovan, B., Padin-Rivera, E., Kowaliw, S. Type of article: 1

Date: 2001

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Transcend

Treatment Dosage: 12w

Exposure: 1

Weekly Dosage: 10h

Demographics of Sample
Age: 49 Female%: 0

Caucasian%: 61

African-American%: 37

Asian American%: 0 Latino%: 2 American Indian%: 0 Other%: 0
%Vets: 100
SUD Type: A

Primary Substance(s): 30 ETOH 70 poly
Trauma Type: n/a

Dropout%: 10

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .32

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .29

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .30

Sample Size: 46

Measurement Time: 1y
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Measurement Instrument: CAPS

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: .21

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: .26

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: .23

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 1y

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .25

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .21

Sample Size: 46

Measurement Instrument: CAPS
Instrument Reliability: n/a

Measurement Time: 6m

Measurement Type: 1
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Hyperarousal PTSD symptoms
Observed Correlation: .17

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 1y

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .30

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .27

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .33

Sample Size: 46

Measurement Instrument: CAPS

Measurement Time: 1y

Measurement Type: 1

Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .40

Sample Size: 46

Measurement Instrument: ASI ETOH

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .40

Sample Size: 46

Measurement Instrument: ASI ETOH

Measurement Time: 1y

Measurement Type: 1

Treatment of Dual Diagnosis 128
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .35

Sample Size: 46

Measurement Instrument: ASI drug

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .33

Sample Size: 46

Measurement Instrument: ASI drug

Measurement Time: 1y

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 27

Title: “Seeking Safety”: outcome of a new cognitive-behavioral

psychotherapy for women with posttraumatic stress disorder and substance dependence
Authors: Najavits, L. M., Weiss, R. D., Shaw, S. R., Muenz, L. R.
Type of article: 1

Date: 1998

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety Exposure: 0

Treatment Dosage: 12w

Weekly Dosage: 3h/w

Demographics of Sample
Age: 35.9

Female%: 100 Caucasian%: 88 African-American%: 12

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: n/a
SUD Type: D

Primary Substance(s): 41 ETOH, 41 Drug, 18 Both
Trauma Type: various

Dropout%: 37

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .28

Sample Size: 11

Measurement Instrument: TSC-40

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms

Measurement Time:
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Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD drug symptoms
Observed Correlation: .26

Sample Size: 11

Measurement Instrument: ASI drug

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .20

Sample Size: 11

Measurement Instrument: ASI drug

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: n/r

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 28a

Title: Seeking Safety therapy for adolescent girls with

PTSD and substance use disorder: a randomized controlled trial
Authors: Najavits, L. M., Gallop, R. J., Weiss, R. D. Type of article: 1

Date: 2006

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety

Treatment Dosage: 3m

Weekly Dosage:

Exposure: 0

2h

Demographics of Sample
Age: 16.06

Female%: 100 Caucasian%: 78.8 African-American%: 3

Asian American%: 12.1 Latino%: 3 American Indian%: 0 Other%: 3
%Vets: 0
SUD Type: A

Primary Substance(s): ETOH + drug
Trauma Type: various

Dropout%: n/a

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:
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Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .55

Sample Size: 18

Measurement Time: post

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .17

Sample Size: 18

Measurement Time: 3m

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .55

Sample Size: 18

Measurement Time: post

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .17

Sample Size: 18

Measurement Time: 3m

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
Other symptoms
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Observed Correlation: .12

Sample Size: 18

Measurement Instrument: APS depression

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
Other symptoms
Observed Correlation: .-.18

Sample Size: 18

Measurement Instrument: APS depression

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
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Article Information
Article ID: 28b

Title: Seeking Safety therapy for adolescent girls with PTSD and

substance use disorder: a randomized controlled trial
Authors: Najavits, L. M., Gallop, R. J., Weiss, R. D. Type of article: 1

Date: 2006

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: n/a

Treatment Dosage: n/a

Exposure: 0

Weekly Dosage:

n/a

Demographics of Sample
Age: 16.06

Female%: 100 Caucasian%: 78.8 African-American%: 3

Asian American%: 12.1 Latino%: 3 American Indian%: 0 Other%: 3
%Vets: 0
SUD Type: A

Primary Substance(s): ETOH + drug
Trauma Type: various

Dropout%: n/aOutcomes

(Dependent Variable)
Total PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:
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Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .18

Sample Size: 15

Measurement Time: post

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .33

Sample Size: 15

Measurement Time: 3m

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .18

Sample Size: 15

Measurement Time: post

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .33

Sample Size: 15

Measurement Time: 3m

Measurement Instrument: APS SUD Measurement Type: 1
Instrument Reliability: n/a
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Other symptoms
Observed Correlation: .01

Sample Size: 15

Measurement Instrument: APS depression

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
Other symptoms
Observed Correlation: .10

Sample Size: 15

Measurement Instrument: APS depression

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
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Article Information
Article ID:29

Title: Seeking safety plus exposure therapy: an outcome study on

dual diagnosis men Authors: Najavits, L. M., Schmitz, M., Gotthardt, S., Weiss, R. D.
Type of article: 1

Date: 2005

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety + Exposure

Exposure: 1 Treatment Dosage: 5m

Weekly Dosage: 30 sessions total

Demographics of Sample
Age: 37.6

Female%: 0

Caucasian%: 100 African-American%: 0

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: 0
SUD Type: D

Primary Substance(s): various
Trauma Type: various

Dropout%: 0

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .85

Sample Size: 5

Measurement Instrument: TSC-40

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Treatment of Dual Diagnosis 138
Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD drug symptoms
Observed Correlation: .81

Sample Size: 5

Measurement Instrument: ASI drug

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: .09

Sample Size: 5

Measurement Instrument: BSI

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a What measured: general psych symptoms
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Article Information
Article ID: 30

Title: Outcome in female patients with both substance use and

post-traumatic stress disorders Authors: Brown, P. J. Type of article: 1

Date: 2000

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: ip

Treatment Dosage: n/a

Exposure: 0

Weekly Dosage: n/a

Demographics of Sample
Age: 35.24

Female%: 100 Caucasian%: 86 African-American%: n/a

Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: n/a
%Vets: n/a

Primary Substance(s): 35 ETOH, 35 drug, 31 both

SUD Type: na Trauma Type: various

Dropout%: 0

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .43

Sample Size: 29

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:
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Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .62

Sample Size: 29

Measurement Instrument: TLFB

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .62

Sample Size: 29

Measurement Instrument: TLFB

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 31

Title: Exposure therapy in the treatment of PTSD among cocaine-

dependent individuals: preliminary findings
Authors: Brady, K. T., Dansky, B. S., Back, S. E., Foa, E. B., Carroll, K. M.
Type of article: 1

Date: 2001

Treatment (Independent Variable)
Type of Treatment: 1
Exposure: 1

Treatment Subtype: Exposure and relapse prevention

Treatment Dosage: 16w

Weekly Dosage: 1-3h

Demographics of Sample
Age: 33.5

Female%: 86.7 Caucasian%: 53.3

African-American%: 46.7

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 0
%Vets: n/a
SUD Type: D

Primary Substance(s): cocaine
Trauma Type: various

Dropout%: 62

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .49

Sample Size: 15 Measurement Time: post

Measurement Instrument: MISS, IES, CAPS Measurement Type: 1
Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .67

Sample Size: 7 Measurement Time: 6m

Measurement Instrument: MISS, IES, CAPS Measurement Type: 1
Instrument Reliability: n/a
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Re-experiencing PTSD symptoms
Observed Correlation: .44

Sample Size: 15

Measurement Instrument: IES, CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: .28

Sample Size: 7

Measurement Instrument: IES, CAPS

Measurement Time: 6mt

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .37

Sample Size: 15

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Hyperarousal PTSD symptoms
Observed Correlation: .61

Sample Size: 7

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .45

Sample Size: 15

Measurement Instrument: IES, CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Avoidance PTSD symptoms
Observed Correlation: .56

Sample Size: 7

Measurement Instrument: IES, CAPS

Measurement Time: 6m

Measurement Type: 1
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Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .38

Sample Size: 15

Measurement Instrument: ASI ETOH

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .55

Sample Size: 7

Measurement Instrument: ASI ETOH

Measurement Time: 6m
Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .62

Sample Size: 15

Measurement Instrument: ASI drug

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .71

Sample Size: 7

Measurement Instrument: ASI drug

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: .38

Sample Size: 15

Measurement Instrument: BDI

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
Other symptoms
Observed Correlation: .92

Sample Size: 7

Measurement Time: 6m
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Measurement Instrument: BDI

Measurement Type: 1

Instrument Reliability: n/a What measured: depression

Treatment of Dual Diagnosis 145
Article Information
Article ID: 33

Title: A cognitive-behavioral treatment for incarcerated women

with substance abuse disorder and posttraumatic stress disorder: findings from a pilot
study Authors: Zlotnick, C, Najavits, L. M., Rohsenow, D. J., Johnson, D. M.
Type of article: 1

Date: 2003

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety Exposure: 0

Treatment Dosage: 12w

Weekly Dosage: 3h

Demographics of Sample
Age: 31.9 Female%: 100 Caucasian%: 66.7 African-American%: 11.1
Asian American%: 0 Latino%: 5.6 American Indian%: 0 Other%: 16.7
%Vets: n/a
SUD Type: D

Primary Substance(s): 50 cocaine, 22.2 ETOH and drugs
Trauma Type: various

Dropout%: n/a

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .69

Sample Size: 18

Measurement Instrument: CAPS

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .52

Sample Size: 18

Measurement Instrument: CAPS
Instrument Reliability: n/a
Re-experiencing PTSD symptoms

Measurement Time: 3m

Measurement Type: 1
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Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .61

Sample Size: 18

Measurement Time: 3m

Measurement Instrument: ASI ETOH Measurement Type: 1
Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .78

Sample Size: 18

Measurement Time: 3m

Measurement Instrument: ATI drug Measurement Type: 1
Instrument Reliability: n/a
Other symptoms
Observed Correlation: n/a

Sample Size:

Measurement Instrument:

Measurement Type:

Instrument Reliability: What measured:

Measurement Time:
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Article Information
Article ID: 35

Title: Comorbid posttraumatic stress disorder and substance use

disorders: treatment outcomes and the role of coping
Authors: Brown, P. J., Read, J. P., Kahler, C. W.

Type of article: 2

Date: 2003

Treatment (Independent Variable)
Type of Treatment: 2

Treatment Subtype: ip

Treatment Dosage: n/a

Exposure: 0

Weekly Dosage: n/a

Demographics of Sample
Age: 37 Female%: 51 Caucasian%: 90 African-American%: n/a
Asian American%: n/a Latino%: n/a American Indian%: n/a Other%: n/a
%Vets: n/a

Primary Substance(s): n/a

SUD Type: n/a

Trauma Type: various

Dropout%: 10

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .46

Sample Size: 55

Measurement Instrument: CAPS

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:
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Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .56

Sample Size: 55

Measurement Instrument: TLFB

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: .56

Sample Size: 55

Measurement Instrument: TLFB

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
Other symptoms
Observed Correlation: .30

Sample Size: 55

Measurement Instrument: SC-90

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a What measured: general psych symptoms
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Article Information
Article ID: 36

Title: A pilot study of seeking safety with OEF/OIF veterans

Authors: Norman, S. B., Wilkins, K. C., Tapert, S. F., Lang, A. J., Najavits, L. M.
Type of article: 3

Date: 2010

Treatment (Independent Variable)
Type of Treatment: 1

Treatment Subtype: Seeking Safety

Treatment Dosage: 10w

Exposure: 0

Weekly Dosage: 1.5h

Demographics of Sample
Age: 32.11

Female%: 0

Caucasian%: 66.7 African-American%: 22.2

Asian American%: 0 Latino%: 0 American Indian%: 0 Other%: 11.11
%Vets: 100

Primary Substance(s): 77.8 ETOH, 22.2 cannibis

SUD Type: n/a

Trauma Type: n/a

Dropout%: 36

Outcomes (Dependent Variable)
Total PTSD symptoms
Observed Correlation: .31

Sample Size: 9

Measurement Instrument: PCL-military

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .75

Sample Size: 4

Measurement Instrument: PCL-military

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a
Total PTSD symptoms
Observed Correlation: .55

Sample Size: 4

Measurement Time: 6m
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Measurement Instrument: PCL-military

Measurement Type: 1

Instrument Reliability: n/a
Re-experiencing PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Hyperarousal PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Avoidance PTSD symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
SUD alcohol symptoms
Observed Correlation: .22

Sample Size: 9

Measurement Instrument: AUDIT

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a
SUD alcohol symptoms
Observed Correlation: .49

Sample Size: 4

Measurement Instrument: AUDIT
Instrument Reliability: n/a
SUD alcohol symptoms

Measurement Time: 3m

Measurement Type: 1
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Observed Correlation: .55

Sample Size: 4

Measurement Instrument: AUDIT

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a
SUD drug symptoms
Observed Correlation: n/a

Sample Size:

Measurement Time:

Measurement Instrument:

Measurement Type:

Instrument Reliability:
Other symptoms
Observed Correlation: .41

Sample Size: 9

Measurement Instrument: BDI-II

Measurement Time: post

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
Other symptoms
Observed Correlation: .74

Sample Size: 4

Measurement Instrument: BDI-II

Measurement Time: 3m

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
Other symptoms
Observed Correlation: .19

Sample Size: 4

Measurement Instrument: BDI-II

Measurement Time: 6m

Measurement Type: 1

Instrument Reliability: n/a What measured: depression
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Appendix B: Coding Definitions
Article Information
Article ID: Unique 3 digit number used to identify study. Will start at 001 and increase
with each study
Title: Title of article
Authors: Authors of article
Type of Article: Single digit code defined as follows: Peer-reviewed journal = 1; Book
chapter = 2; Technical/research report = 3; Presentation = 4; Dissertation = 5; Thesis = 6;
Other = 7
Date: Publication or presentation year
Treatment (Independent Variable)
Type of Treatment: Single digit code defined as follows: Integrated treatment = 1; Nonintegrated treatment SUD focused = 2; Non-integrated treatment PTSD focused = 3;
Non-integrated treatment Other = 4; No-treatment Control = 5
Treatment Subtype: Name of Treatment (e.g. Seeking Safety or CBT)
Exposure: Presence of an exposure based component in treatment: 0 = No exposure; 1 =
exposure
Treatment Dosage: Number of weeks of treatment
Weekly Dosage: Treatment hours per week
Age: Mean age of sample
<Demographics>%: % of individuals undergoing treatment type in each demographic
category.
Primary Substance: Primary substance used by participants in study
SUD Type: Abuse or Dependence
Trauma type: type of trauma - 0 = unknown; 1 = childhood; 2 = military; 3 = accident;
4 = violence
Dropout %: % of individuals who did not complete treatment for any reason
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Outcomes (Dependent Variable)
Sample Size: Number of individuals undergoing that treatment
Measurement Time: Number of weeks after pretest
Observed Correlation: Study observed effect size in r between pre and post tests
Measurement Instrument: Name of instrument
Measurement Type: Single digit code defined as follows: Self-report = 1; Physiological
measure = 2; Behavioral Observation = 3
Instrument reliability: Reliability of instrument
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Appendix C: Transformations (Rosenthal, 1994)*
t: r=t/√(t2+df)
F: r=√(F/(F+df))
χ2: r=√(χ2/n)
z: r=z/√n
Pre-post difference: d = (m1 – m2)/sd
p: Consult z-distribution table and set to t
d: r=d/√(d2+4)
*

Other conversion formulae were used for statistics not listed here.
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Appendix D: Corrections (Hunter & Schmidt, 2004)
Formulae

Definitions

Attenuation: rc=r/(√(rxx)* √(ryy))

rc: corrected correlation

Construct Validity: rc =r/(a1*a2)

r: observed correlation

50/50 Dichotomization: rc =r/.8

rxx: dependent variable reliability

90/10 Dichotomization: rc =r/.59

ryy: independent variable reliability

Multiple Measures: rc =∑rxy/√(k+k(k-1) rxx )

a1 and a2: construct validities

Range Restriction: rc =((σe/σr)*r)/√(((σe/σr)2-1)r2+1) k: # of intermeasure correlations
Correlation Bias: rc =r/((2N-3)/(2N-2))

rxx : average of off-diagonal
correlations between measures
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Appendix E: Basic Meta-analysis formulae (Hunter & Schmidt, 2004)
Definitions

Formulae
r = ∑(Niri)/∑Ni *

r : Corrected mean correlation

σr2 = ∑(Ni(ri- r )2)/∑Ni *

Ni: Study sample size

σe2 = (1- r 2)2/( N - 1)

ri: Observed study correlation
σr2: Observed variance

N =N/K
σp2 = σr2 - σe2

σe2: Expected variance

Rel(r) = σe2/σr2

N: Total sample size

*Substitute NiAi for Ni and rc for ri
to weight by error

K: Number of studies
N : Average sample size

x=K( r / r

c -1)

σp2: Corrected variance
Rel(r): Reliability of study
correlations
Ai: Attenuation factor (denominators
of corrections + Range restriction
formula (p. 122))
r c: Critical value for the
correlation
x: Number of studies averaging null
results needed to bring the observed
correlation down to the critical value

